Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
12/2010 | Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
12/30/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100331234 - Aminoalcohol lipidoids and uses thereof: Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and... Agent: Wolf Greenfield & Sacks, P.C.

20100331233 - Crystal of xpa and ercc1 complex and uses thereof: The present invention relates to complexes and crystals of an XPA peptide and an ERCC1 peptide, and structural coordinates of the complex obtained from such crystals. The coordinates are useful for identifying compounds that bind to ERCC1 and inhibit binding of XPA, and thus inhibitors of nucleotide excision repair (NER).... Agent: Kenyon & Kenyon LLP

20100331235 - Histidine and/or histidine derivative for the treatment of inflammatory skin diseases: Histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject. In some embodiments, the histidine and/or a derivative thereof is used for the prevention and/or treatment of an inflammatory skin disease.... Agent: Conley Rose, P.C. David A. Rose

20100331232 - Starch-based hydrogel for biomedical applications: A starch-based hydrogel for the controlled delivery of a biologically active agent is described. The hydrogel comprises a dispersed phase, and a dispersion medium consisting substantially of water. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the... Agent: Margaret J. Mclaren, P.A. Mclaren Legal Services

20100331236 - Cyclic peptides as g-protein coupled receptor antagonists: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages.... Agent: Haynes And Boone, LLPIPSection

20100331237 - Gag binding proteins: e

20100331238 - Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the... Agent: Arena Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100331239 - Cd14 and peptides thereof for protection of cells against cell death: Provided is a method of using soluble CD14 or peptides derived therefrom for protecting cells from death, specifically from apoptotic cell death. Further provided are compositions including CD14 or CD14 peptides and methods for protecting cells, in particular lymphocytes, from apoptotic cell death. The compositions and methods are relevant, in... Agent: The Nath Law Group

20100331240 - Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins: The present invention provides methods of treatment and/or prevention of infections, for example, viral and bacterial infections, in individuals, wherein the method comprises administering a supraphysiological amount of mannose-binding lectin (MLB) and/or ficolin-MBL fusion protein to an individual afflicted with an infection or at risk of an infection, such as... Agent: David S. Resnick

20100331241 - Bacteriocins and novel bacterial strains: Novel bacteriocins and/or the novel lactic acid-producing strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20100331242 - Method of using lectins for prevention and treatment of oral and alimentary tract disorders: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20100331243 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100331244 - Pharmaceutical composition, food or drink, and methods related thereto: A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of... Agent: Oliff & Berridge, PLC

20100331245 - Peptide yy analogs: The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.... Agent: Alan F. Feeny, Esq.

20100331246 - Ester-based insulin prodrugs: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and... Agent: Barnes & Thornburg LLP

20100331247 - Peptide therapy for hyperglycemia: Methods of modulating blood glucose levels treating hyperglycemia and related complications and conditions by administration of a VGF biomolecule to a patient in need of such treatment are provided. Methods of enhancing insulin secretion from islet beta cells in a mammal exhibiting reduced insulin secretion by administration of a therapeutically... Agent: Michael Best & Friedrich LLP

20100331248 - Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide: Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline (LSF) is an immunomodulator that reduces cytokine signaling and reduces the onset... Agent: Nixon & Vanderhye, PC

20100331249 - Pharmaceutical composition for inhibiting peritoneal dissemination: A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100331250 - Anti-angiogenesis fusion proteins: The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged... Agent: Morrison & Foerster LLP

20100331251 - Polypeptides homologous to vegf and bmp1: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be... Agent: Genentech, Inc.

20100331252 - Myostatin inhibitor enhancement of musculoskeletal repair: The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide... Agent: Benjamin Aaron Adler Adler & Associates

20100331253 - Method for cell adhesion and wound healing: The present invention relates to a method for cell adhesion and wound healing with internal domains of βig-h3. Particularly, the present invention relates to the method of using recombinant proteins comprising one or more of 2nd or 4th internal domain of βig-h3 for cell adhesion and wound healing, wherein the... Agent: Jhk Law

20100331254 - Pulverized fibrin clots and pharmaceutical compositions containing them: Provided is a pulverized fibrin clot and a pharmaceutical composition including a pulverized fibrin clot. The pharmaceutical composition may contain the pulverized fibrin clot suspended in a gel such as cross-linked hyaluronic acid. The pharmaceutical composition may be in a form suitable for injection and may be used, for example,... Agent: The Nath Law Group

20100331255 - Compositions and methods for increasing production of recombinant gamma-carboxylated proteins: Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed by way of genetically engineered cell lines which over-express VKORC1. Also disclosed is the antisense inhibition of expression of calumenin in conjunction with overexpression of VKORC1 which also increases expression of functional gamma-carboxylated proteins. Gamma-carboxylated proteins of interest may... Agent: Dann, Dorfman, Herrell & Skillman

20100331256 - Variants of c-type natriuretic peptides: The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and/or substitutions with natural amino acids, unnatural amino acids and/or peptidomimetics (including peptide bond isosteres); amino acid extensions; and/or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants... Agent: Marshall, Gerstein & Borun LLP (biomarin)

20100331257 - Preparation of terminally-sterilized collagen that is soluble at neutral ph: Terminally sterilized collagen that is soluble at a neutral pH is useful for medical uses. The invention also relates to the method for preparing such terminally sterilized collagen.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20100331258 - memory in subjects with mini-mental state examination of 24-26: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally... Agent: Foley And Lardner LLP Suite 500

20100331259 - Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects.: Use of a neurotoxic component of a Clostridium botulinum toxin complex for the facial cosmetic treatment of a human or animal susceptible to suffering from doll's face or frozen face, or the neurotoxic component of a Clostridium botulinum toxin complex for the treatment of a disease or disorder caused by... Agent: The Firm Of Hueschen And Sage

20100331260 - Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same: The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100331261 - Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome: The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or... Agent: Buchanan, Ingersoll & Rooney PC

20100331262 - Peptide vaccine using mimic molecules of amyloid beta peptide: This invention is intended to discover a peptide that induces production of an antibody specific for an abnormal amyloid β peptide from mimic peptides of the amyloid β peptide and to utilize the same as a vaccine or immunogen. This invention relates to a pharmaceutical composition containing a peptide consisting... Agent: Birch Stewart Kolasch & Birch

20100331263 - Methods and compositions for inhibiting angiogenesis: The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.... Agent: Casimir Jones, S.c.

20100331264 - Preserving secondary peptide structure: A method of preserving the α-helix secondary structure of N-Acetyl-D-Asp-D-Trp-D-Phe-D-Lys-D-Ala-D-Phe-D-Tyr-D-Asp-D-Lys-D-Val-D-Ala-D-Glu-D-Lys-D-Phe-D-Lys-D-Glu-D-Ala-D-Phe-Amide or N-Acetyl-L-Asp-L-Trp-L-Phe-L-Lys-L-Ala-L-Phe-L-Tyr-L-Asp-L-Lys-L-Val-L-Ala-L-Glu-L-Lys-L-Phe-L-Lys-L-Glu-L-Ala-L-Phe-Amide and compositions comprising such peptides are disclosed.... Agent: Novartis Corporate Intellectual Property

20100331266 - Analysis of amino acid copolymer compositions: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.... Agent: Fish & Richardson P.C. (bo)

20100331265 - Methods for the prevention and treatment of burn injuries and secondary complications: The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage.... Agent: Foley & Lardner LLP

20100331267 - Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies: The present invention relates to methods for treating α-synucleinopathies, methods for modulating of assembly, folding, accumulation, oligomerization, rate of aggregation, oligomerization and clearance of proteins of fragments comprising α-synuclein aggregates in a subject, by administering a medicament comprising a therapeutically effective amount of a cyclohexanehexyl derivative. More specifically, the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100331268 - Nitrated lipids and methods of making and using thereof: Described herein are nitrated lipids and methods of making and using the nitrated lipids.... Agent: Mckeon Meunier Carlin & Curfman LLC

20100331270 - Adrenomedullin production enhancer: It is an object of the invention to discover a substance that effectively increases the production of adrenomedullin, as well as to provide an adrenomedullin production-enhancing agent utilizing this substance. The adrenomedullin production-enhancing agent is characterized by inclusion of a ginsenoside, a sanshool, and/or a shogaol as active ingredients.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100331269 - Triterpenes derivatives and uses thereof as antitumor agents or anti-inflammatory agents:

20100331271 - Use of acacetin and related compounds as potassium channel inhibitors: This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (IKur or IKsus), transient outward potassium (Ito), and acetylcholine-activated potassium current (IK.ACh).... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100331272 - Agent for preventing or ameliorating skin aging: An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging, containing triterpenoid saponins represented by the following formula (1) as an active... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100331273 - Self-assembling complex for targeting chemical agents to cells: The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted... Agent: Davis Wright Tremaine LLP/los Angeles

20100331392 - Antidotes to antisense compounds: The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.... Agent: Knobbe, Martens, Olson & Bear, LLP

20100331389 - Compositions and methods for the specific inhibition of gene expression by dsrna containing modified nucleotides: The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in a eukaryotic cell.... Agent: Edwards Angell Palmer & Dodge LLP

20100331393 - Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers: The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers.... Agent: Dla Piper US LLP

20100331390 - Effects of apolipoprotein b inhibition on gene expression profiles in animals: Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese... Agent: Jones Day

20100331394 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20100331391 - Zap-70 as predictor and modulator of effector function of t cells: In this application is described a novel, multiparameter analysis of TCR-coupled signaling and function in resting and activated naive and memory CD4 T cells, revealing a biochemical basis for immunological recall. Results reveal a novel biochemical signature imparted to memory CD4 T cells enabling efficacious responses through increased ZAP-70 expression... Agent: University Of Maryland, Baltimore/pratt

20100331397 - 2-5a analogs and their methods of use: Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, a bacterial infection, cancer and/or parasitic disease.... Agent: Knobbe Martens Olson & Bear LLP

20100331395 - Decoy-containing pharmaceutical compositions and method of using the same: A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB... Agent: Ropes & Gray LLP

20100331396 - Neostatins: The invention provides fragments of type XVIII collagen termed neostatins, and methods for their use in the treatment of opthalmological disorders associated with angiogenesis.... Agent: Fish & Richardson P.C. (bo)

20100331274 - Antiaging chirally-correct mitoprotectant amino acid and peptide complexes: This invention relates to certain chirally-correct mitoprotectant phosphorylated heterocyclic agents [formula (I)], which are useful for the treatment of dermatological disorders that include challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction; age spots; acne, loss of cellular antioxidants; skin changes associated with aging including collagen loss,... Agent: Shyam K. Gupta Bioderm Research

20100331275 - Supporting activities of daily living: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication... Agent: Foley And Lardner LLP Suite 500

20100331276 - Topical compositions and the use thereof: The invention relates to a composition for topical application as well as the use of such a composition. The invention is characterised in that it comprises at least one first and one second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100331277 - Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin: e

20100331278 - Uses of cationic hydroxyethylcellulose in oral ingestion forms, and prevention and treatment of metabolic disorders: Described are an oral ingestion form comprising cationic hydroxyethylcellulose, and methods of using the same in prevention and treatment of metabolic disorders.... Agent: The Dow Chemical Company

20100331279 - Inhibition of antigen presentation with poorly catabolized polymers: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For... Agent: Dla Piper LLP (us)

20100331280 - Modulation of the phospholipase a2 pathway as a therapeutic: There is provided a method of modifying vasoactivity by regulating a soluble Aβ pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble Aβ pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble Aβ pro-inflammatory... Agent: Bryan Cave LLP

20100331281 - Phospholipid compositions and uses thereof: We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids... Agent: Clark & Elbing LLP

20100331282 - Pyridine derivative containing ((phosphonooxy)methyl)pyridinium ring, and antifungal agent containing these derivative:

20100331283 - Mitotic kinesin inhibitors and methods of use thereof: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.... Agent: Viksnins Harris & Padys Pllp

20100331284 - Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present... Agent: Seed Intellectual Property Law Group PLLC

20100331285 - Novel polymorph of acetylsalicylic acid, and methods of making and using the same: A polymorph of aspirin is provided by the present invention. Methods of making and using the same are also provided.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100331286 - Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function: The field of the present invention relates to novel and improved therapies for treatment of complications associated with impaired renal function. More specifically, the present invention relates to evaluating the effects of a novel renal multivitamin on Vitamin D levels, EPO dose, inflammatory (e.g., C-reactive protein) and other biomarkers in... Agent: Craig A Crandall, Apc

20100331287 - 6-(aminoalkyl)indazoles: 6-(Aminoalkyl)indazoles of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, and renal, cardiac and vascular protecting medicinally active ingredients.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100331289 - Combination of azelastine and steroids: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.... Agent: Conley Rose, P.C.

20100331288 - Crystalline hydrate of betamimetika and use as medicament thereof: The present invention relates to a crystalline, enantiomerically pure hydrate of R-6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one-hydrochloride of formula (1) and its activity as a long-acting betamimetic, on its own or combined with one or more other active substances for treating respiratory complaints.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100331290 - Taxane delivery system: Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.... Agent: Morrison & Foerster LLP

20100331291 - Process for the preparation of drospirenone: A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action by the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β, 16β-dimethylene-5β-androstane-3β,5,17β-triol.... Agent: Abelman, Frayne & Schwab

20100331292 - Substituted 16,17-annellated steriod compounds for use in womens healthcare: Wherein R1 is H or halogen; R2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R3 is H or halogen; R4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl; R5 is methyl or ethyl; R6 is H or methyl; R7 is H or methyl; R8 is H or acyl for use in the... Agent: Organon Usa, Inc. C/o Merck

20100331293 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20100331294 - 4-substituted-2-amino-pyrimidine derivatives: b

20100331301 - Azetidine compound and pharmaceutical use thereof:

20100331299 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20100331300 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20100331296 - Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors: The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100331298 - Carboxamide compounds and their use: Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.... Agent: Goodwin Procter LLP Patent Administrator

20100331297 - Modulation of protein trafficking: Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically... Agent: Fish & Richardson P.C. (ny)

20100331295 - Modulators of lxr: Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100331302 - N-(2-(hetaryl)aryl) arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as... Agent: Brinks Hofer Gilson & Lione

20100331303 - Prolyl hydroxylase inhibitors and methods of use: The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.... Agent: Fsb Fisherbroyles, A Limited Liability Partnership

20100331304 - Compounds which modulate the cb2 receptor: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100331306 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20100331308 - Oxazolidinone derivatives: b

20100331305 - Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK... Agent: Genentech, Inc.

20100331307 - Therapeutic compounds and compositions: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.... Agent: Lando & Anastasi, LLP

20100331309 - Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid: m

20100331310 - Bicycloamine derivatives:

20100331311 - Galantamine as a neuroprotective drug for retinal ganglion cells: The present invention relates to the use of galantamine for neuroprotection of retinal ganglion cells.... Agent: Smart & Biggar

20100331312 - Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto: Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of... Agent: Fish & Richardson P.C.

20100331314 - Pyrazolopyrimidines and related heterocycles as kinase inhibitors: The invention provides compounds of general formula (I) that inhibit selected kinases (Pim and/or CK2 kinases) and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain infections and immunological disorders.... Agent: Cooley LLP Attn: Patent Group

20100331315 - Rhodanines and related heterocycles as kinase inhibitors: The invention provides compounds that inhibit PIM kinases and/or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.... Agent: Cooley LLP Attn: Patent Group

20100331313 - Thiazole derivatives as protein kinase inhibitors: The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection,... Agent: Merck Patent Department (k-6-1, 1990)

20100331316 - 5-phenyl-lh-benz0 [e] [1,4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors: Novel hydroxamate histone deacetylase inhibitors of formula (I) wherein X is C═O or CH2 used as antineoplastic agent.... Agent: Steinfl & Bruno

20100331317 - Benzodiazepine compound and pharmaceutical composition: v

20100331318 - Azatricyclic antibiotic compounds:

20100331319 - Novel compound useful for the treatment of degenerative and inflammatory diseases: A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection,... Agent: Klauber & Jackson

20100331320 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention... Agent: Foley & Lardner LLP

20100331321 - Bis-(sulfonylamino) derivatives for use in therapy: The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100331322 - Substituted piperidines as renin inhibitors: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100331323 - Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives: The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.... Agent: Myers Bigel Sibley & Sajovec

20100331324 - Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100331325 - Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives: s

20100331326 - Inhibitors of cyp 17:

20100331327 - 7-substituted indirubin-3'oximes and their applications: The invention relates to new 3′-, 7-substituted-indirubins of formula (I) wherein R represents N—OH, N—O-alkyl or N—O—CO-alkyl, NO—(Ra)n1-Het, N—O—(Y)n1—NRaRb, N—O—CO—N(RbRc), radical with Het representing an aliphatic nitrogeneous heterocycle, Y being an optionally substituted —CH2— radical, n1 being 1 to 3, and X is an halogen atom selected in the group... Agent: Nixon & Vanderhye, PC

20100331328 - Bicyclylaryl-aryl-amine compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and... Agent: Swanson & Bratschun, L.L.C.

20100331329 - Benzamide derivatives useful as histone deacetylase inhibitors: e

20100331330 - Methods and compositions for treating ischemic stroke: A method of treating a cerebrovascular accident in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the subject after onset of ischemia sufficient to a cause the cerebrovascular accident and prior to reperfusion.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100331331 - Therapeutic compositions and the use thereof: The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome P-450, or a pharmaceutically acceptable salt thereof.... Agent: Viksnins Harris & Padys Pllp

20100331332 - Methods for treating drug addiction and improving addiction-related behavior: The invention is directed to a method of treating addiction to drugs of abuse in a subject, comprising administering a therapeutically effective amount of a cabamoyl compound, or pharmaceutically acceptable salt or ester thereof.... Agent: Michael Best & Friedrich LLP

20100331333 - Imidazo [1,2-b] pyridazine compounds: e

20100331334 - Inhibitors of mek: This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.... Agent: Millen, White, Zelano & Branigan, P.C.

20100331335 - Inhibitors of jun n-terminal kinase: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100331336 - Protective effect of high dose folate on mycardial ischemia: The present invention relates to the use of high dose of folic acid, or an equivalent dose one of its biological active derivatives to blunt myocardial dysfunction during ischemia and to ameliorate post-reperfusion injury. The invention specially relates to an early treatment by the application of a high dose of... Agent: Traskbritt, P.C.

20100331337 - Quercetin-containing compositions: This invention relates to a composition containing quercetin, vitamin B3, vitamin C, and folic acid. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100331338 - Glucokinase activators: Novel compounds of the Formula (I) in which R1, R2, R3, and R4 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Type 1 and 2, obesity, neuropathy and/or nephropathy.... Agent: Millen, White, Zelano & Branigan, P.C.

20100331339 - (1-azinone)-substituted pyridoindoles: wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5; is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R6, —C(═O)—O—R7, or —C(═O)—NR19R20; R6 and R7 are each optionally substituted alkyl... Agent: Nixon Peabody LLP - Patent Group

20100331340 - Use of aryl piperazine derivatives in manufacturing medicants for treating pain: The use of aryl piperazines of formula (I) in manufacturing a medicament for treating acute pain, neuropathic pain or receptive nociceptive pain in mammals including human beings is disclosed.... Agent: Myers Bigel Sibley & Sajovec

20100331341 - 2-carboxamide-7-piperazinyl-benzofuran derivatives 774: e

20100331342 - Immuno inhibitory pyrazolone compounds: Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R1 and R2 independently represent H, or C1-C6 alkyl; R3 represents H; F; Cl; Br;... Agent: Banner & Witcoff, Ltd.

20100331343 - Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100331344 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100331345 - Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors: in which each substituent of formula (I) is as defined in the specification. The present invention also relates to preparation methods of compounds represented by formula (I), a pharmaceutical composition comprising compounds represented by formula (I) and usage of compounds represented by formula (I) for treating chronic neurodegenerative diseases such... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20100331346 - Beta-amino acid derivatives for treatment of diabetes:

20100331347 - (en) 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof:

20100331348 - Tropane derivatives useful as pesticides: Compounds of formula (I) wherein the substituents have the meanings assigned to them in claim 1, are useful as pesticides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100331349 - Use of gamma-aminobutyric acid to mask or reduce an unpleasant flavour impression and preparations containing gamma-aminobutyric: The use of γ-aminobutyric acid or a physiologically acceptable salt of γ-aminobutyric acid to mask or reduce the unpleasant flavour impression of an unpleasantly tasting substance is described. The food, beverage or oral care preparations or oral pharmaceutical preparations comprising at least one unpleasantly tasting substance and γ-aminobutyric acid are... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100331350 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100331351 - Methods and compositions for treating bacterial infection: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.... Agent: Casimir Jones, S.c.

20100331352 - Novel crystalline forms of bosentan: The present invention relates to novel crystalline forms of bosentan and processes for their preparation. Further, the invention relates to pharmaceutical compositions comprising said crystalline forms and use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100331353 - 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof: e

20100331354 - Intranasal opioid compositions: The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodiments of the present invention, the pharmaceutical compositions have improved bioavailability.... Agent: Stites & Harbison PLLC

20100331355 - Substituted quinolines for the treatment of cancer: e

20100331356 - Self-microemulsifying drug delivery systems: Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.... Agent: Arent Fox LLP

20100331357 - Pharmaceutical composition: The present invention provides a pharmaceutical composition, wherein solubility and stability of a water-insoluble or slightly water-soluble compound represented by formula (I): wherein each symbol is as defined in the specification, are improved, by combination of the above-mentioned compound and a cyclodextrin derivative and a method for improving solubility, stability... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100331358 - Tetrahydrofuropyridones: The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck

20100331359 - Novel compound useful for the treatment of degenerative and inflammatory diseases: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations,... Agent: Klauber & Jackson

20100331360 - 3-substituted sulfonyl piperidine derivative: wherein n1, n2, and n3 are 0, 1, or 2, respectively; R1 represents C1-6 alkyl, C3-8 cycloalkyl, or the like; R2 represents aryl or heteroaryl; R3 represents a hydrogen atom, C1-6 alkyl, or the like; and M1, M2, M3, and M4 independently represent a hydrogen atom, C1-6 alkyl, or the... Agent: Merck

20100331361 - Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy: A pharmaceutical composition including active ingredients of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl-2-methoxybenzene-1-sulfonamide and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester, or their pharmaceutically acceptable salts, provides improvement of lower urinary tract symptoms associated with prostatic hypertrophy. The active ingredients may be administered either simultaneously or at a time interval. The pharmaceutical composition also provides significant improvement of... Agent: Fitzpatrick Cella Harper & Scinto

20100331362 - Treatment method for anemia: The present invention relates to improved methods for treating anemia. Methods and compounds useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided.... Agent: Fibrogen, Inc.

20100331363 - Treatment of mitochondrial disorders using a farnesyl transferase inhibitor: Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100331364 - Treatment of hfnef: The invention relates to perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of HfnEF, as well as to a method of treating HfnEF, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said... Agent: Hoffmann & Baron, LLP

20100331365 - Piperidine derivative: The present invention provides a compound a piperidine derivative having excellent histamine receptor antagonistic action, which is useful as active ingredients of a pharmaceutical composition, especially an antihistamine. The piperidine derivative of the present invention has a potent histamine receptor antagonistic action. Further, the compound of the present invention shows... Agent: Oliff & Berridge, PLC

20100331366 - N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase: Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful... Agent: High Point Pharmaceuticals, LLC

20100331367 - N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands: v

20100331368 - 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents: Novel dicationic 2,5-diaryl selenophene compounds are described. Also described are novel aza analogues of dicationic 2,5-diaryl thiophenes. The presently disclosed dicationic compounds exhibit in vitro activity versus Trypanosoma brucei rhodesiense, Plasmodium falciparum, and/or Leishmania donovani comparable to that of pentamidine and furamidine. Some of the novel dicationic compounds display good... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100331369 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100331370 - Novel isobenzofuran analogs of sclerophytin a: Isobenzofuran analogs of sclerophytin A are prepared in a highly concise fashion via an aldol-cycloaldol sequence. The analogs exhibit IC50's as low as 1 μM in growth inhibitory studies against KB3 cells using an MTT assay. Preferred analogs have one of the following structural formulas, where R is hydrogen or... Agent: Medicus Associates

20100331371 - Methyl-benzimidazole derivatives: o

20100331372 - Pyridin-2-yl derivatives as immunomodulating agents:

20100331373 - Drug-containing nanoparticles: The present invention relates to nanoparticles containing pioglitazone or a salt thereof and a biocompatible polymer, a pharmaceutical preparation containing the nanoparticles for the prophylaxis or treatment of arteriosclerotic diseases, and a stent carrying the nanoparticles. Using the nanoparticles of the present invention, rupture of arteriosclerotic plaque can be suppressed,... Agent: Foley And Lardner LLP Suite 500

20100331375 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, Ar1, R1, R2, R3, R4, R6, R7, R8, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20100331374 - Prolyl hydroxylase inhibitors and methods of use: The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.... Agent: Fsb Fisherbroyles, A Limited Liability Partnership

20100331376 - Process for recovering flunixin from pharmaceutical compositions: This invention is generally directed to a method for recovering flunixin and flunixin analogs from pharmaceutical compositions. The recovered flunixin and analogs can be, for example, reused to make new pharmaceutical compositions and thereby reduce the need and expense of manufacturing new flunixin and flunixin analogs.... Agent: Intervet/schering-plough Animal Health

20100331377 - Compositions and methods for wound care: The present disclosure relates to compositions for and methods of repairing the stratum corneum, compositions and methods for inhibiting excessive transepidermal water loss, compositions for and methods of treating skin that is distressed or wounded as a result of a disease or other biological condition or process (as distinguished from... Agent: Bryan Cave LLP

20100331378 - Aminotriazole derivatives as alx agonists: e

20100331379 - Benzamide glucokinase activators: The present invention relates to N-heteroaryl-benzamides, pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful in diseases or medical conditions mediated by glucokinase.... Agent: Townsend And Townsend And Crew, LLP

20100331380 - Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20100331381 - Substituted phenylureas and phenylamides as vanilloid receptor ligands: The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.... Agent: Crowell & Moring LLP Intellectual Property Group

20100331382 - Processes of making and using pharmaceutical formulations of antineoplastic agents: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent... Agent: Merck Patent Department (k-6-1, 1990)

20100331383 - Compounds for the treatment of aids and other viral diseases: or salts or hydrates thereof in a carrier which minimizes micellar formation or van der Waals attraction of molecules of said compound. The invention also provides S enantiomeric forms of such compounds which possess the ability to inhibit cell growth whilst being of low toxicity to such cells and methods... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100331384 - Guanidine based compounds: The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of... Agent: Scully Scott Murphy & Presser, PC

20100331385 - Pyrazole urea derivatives used as kinase inhibitors: Compounds of Formula (I) where R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof, are useful in the treatment and prevention of various disorders mediated by kinases... Agent: Viksnins Harris & Padys Pllp

20100331386 - Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents: m

20100331387 - Lyophilized pharmaceutical compositions: Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, an chelator/antioxidant, a buffer or buffer component, and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered... Agent: Novartis Corporate Intellectual Property

20100331388 - Crystalline duloxetine hydrochloride: Crystalline duloxetine hydrochloride, compositions containing the same and methods for the production thereof.... Agent: Sunstein Kann Murphy & Timbers LLP

20100331398 - Derives du gossypol et de l'apogossypol, leurs preparations et leurs applictions: Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof.... Agent: Young & Thompson

20100331401 - Antimicrobial and antiinflammatory composition: The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.... Agent: Merchant & Gould PC

20100331400 - Chromene derivatives and use thereof as hif hydroxylase activity inhibitors: The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).... Agent: Foley & Lardner LLP

20100331399 - Polyphenol extraction process: The invention relates to a process for extracting one or more polyphenols from fruits such as apples and to uses of said extracts in the treatment or prophylaxis of cardiovascular disease, colon cancer and digestive health.... Agent: Foley & Lardner LLP

20100331402 - Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder: e

20100331403 - Compounds and methods for the treatment of cancer: The present invention provides methods of synthesizing organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.... Agent: Ropes & Gray LLP Iprm - Floor 43

20100331405 - Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.... Agent: Lee & Hayes, PLLC

20100331404 - Vector delivery-based microbicides: A new class of anti-microbial agents and methods for preventing or reducing the risk of sexually transmitted infections and/or diseases is provided. Preferably, these anti-microbial agents are also contraceptive and, thus, also prevent or reduce the risk of unplanned pregnancies. The anti-microbial agents comprise a delivery vector having anti-microbial activity... Agent: Fenwick & West LLP

20100331406 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent: Philip S. Johnson Johnson & Johnson

20100331407 - Clear ophthalmic solution comprising latanoprost as active ingredient: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method... Agent: Holtz, Holtz, Goodman & Chick PC

20100331408 - Cyclopropanecarboxylate and pest controlling composition containing the same: There is provided a novel cyclopropanecarboxylate compound having an excellent pest controlling effect represented by the formula (1):... Agent: Panitch Schwarze Belisario & Nadel LLP

20100331409 - Use of methyl cinnamate in the inhibition of candida albicans biofilms: The invention provides a method of inhibiting biofilm formation or development of Candida albicans, comprising applying to an object in need thereof an effective amount of methyl cinnamate whereby formation or development of Candida albicans biofilm can be inhibited or prevented. Also provided is a method of treating Candida albicans... Agent: Wpat, PC Intellectual Property Attorneys

20100331410 - Biaryl amides: e

20100331411 - Foamable alcohol compositions, systems and methods of use:

20100331413 - Therapeutic formulations based on asiatic acid and selected salts thereof: A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases.... Agent: Mccracken & Frank LLP

20100331412 - Two container skin care product: A skin product for improving the skin includes a first container containing a first product, the first product including alpha hydroxy acid, and second container containing a second product, the second product including a combination of humectants, moisturizers and an AHA (glycolic acid) formulation.... Agent: Davidson, Davidson & Kappel, LLC

20100331414 - Crystal comprising (2r)-2-propyloctanoic acid and amine: According to the present invention, crystals comprising (2R)-2-propyloctanoic acid and an amine, which can be used as bulk drugs for safely orally administrable solid preparations with keeping the pharmacological effect, are provided. Among these crystals, the crystal with dibenzylamine per se is particularly useful as bulk drug for pharmaceuticals and... Agent: Sughrue-265550

20100331415 - Use of omega-3-fatty acid(s): The invention relates to the use of omega-3-fatty acid(s) in means for pain relief. The means preferably comprise highly unsaturated omega-3-fatty acid(s) that contain, above all, EPA and/or DHA. Preferably, the omega-3-fatty acid is administered in a high dose of more than 2 g, in particular more than 3 to... Agent: Collard & Roe, P.C.

20100331416 - Use of monochlorourea to treat industrial waters: The present invention comprises a method for controlling (e.g. inhibiting) or killing microorganisms in an aqueous environment. The method includes the addition of an effective amount of monochlorourea or modified monochlorourea to an aqueous solution. This aqueous solution may be a cooling water system, a recreational water system, a water... Agent: Joanne Mary Fobare Rossi Hercules Incorporated

20100331417 - Treatment of neural diseases or conditions: Compounds, methods, uses, compositions, kits and packages for the prevention and/or treatment of neural injury or a neurodegenerative disease, based on the use of a retinoic acid derivative, such as fenretinide, and/or analogs, derivatives, pro-drugs, precursors thereof, and/or salts thereof, are described.... Agent: Klarquist Sparkman, LLP

20100331418 - Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal: Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100331423 - Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant: The present invention provides a disinfectant that contains olanexidine in a concentration sufficient to exhibit an effective bactericidal effect, and that has hardly any side effects such as skin irritation. Specifically, the present invention provides a disinfectant containing an aqueous solution that contains olanexidine and at least an equimolar amount... Agent: Sughrue Mion, PLLC

20100331419 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising bupropion, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100331420 - Combination therapies for the treatment of obesity: Described are pharmaceutical compositions comprising sibutramine, metformin, and at least one pharmaceutically acceptable carrier or excipient. Another aspect of the present invention relates to a method of treating a patient suffering from obesity or needing to lose weight, comprising the step of co-administering to said patient a therapeutically effective amount... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100331421 - Disinfectant and/or bactericidal aqueous compositions: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin.... Agent: Sughrue Mion, PLLC

20100331422 - Stable hydroalcoholic compositions: A hydroalcoholic lotion is disclosed which comprises (a) a lower alcohol and water in a weight ratio of about 35:65 to 100:0, and (b) between at least 0.5% and 8% by weight thickener system comprised of at least one emulsifier present in at least 0.05% by weight wherein the composition... Agent: 3m Innovative Properties Company

20100331424 - Use of axomadol for treatment of arthrosis pain: The use of axomadol for the treatment of pain in arthrosis.... Agent: Crowell & Moring LLP Intellectual Property Group

20100331425 - Tapentadol for treating pain due to osteoarthritis: The use of tapentadol for treating pain due to osteoarthritis.... Agent: Crowell & Moring LLP Intellectual Property Group

20100331426 - Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria: Disinfectant which has activity towards mycobacteria and has (a) 1-(2-ethylhexyl} glycerol ether and (b) one or more aromatic alcohols group including aryloxyalkanols, ethers and arylalkanols.... Agent: Young & Thompson

20100331427 - Organic compounds: s

20100331429 - O/w emulsions containing a hydrophobic modified inulin and at least one thickening polysaccharide of plant origin: The invention relates especially to a composition in the form of an oil-in-water emulsion comprising an inner fatty phase and an outer aqueous phase and containing: a) at least 0.01% by weight and preferably at least 0.05% by weight, relative to the total weight of the composition, of at least... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100331428 - Sonic low pressure spray drying: This invention provides methods of spray drying pharmaceutical powders from a vibrating nozzle at low pressures. The method can effectively spray dry thick or viscous solutions or suspensions to provide small uniform particles. The invention includes dry particle compositions prepared by methods of low pressure spraying from vibrating nozzles.... Agent: Satoshi Ohtake

20100331430 - Pharmaceutical compositions containing propionic preservative components: The invention provides ophthalmic compositions preserved using propionic preservative components alone or in combination with at least one additional preservative. In particular, an improvement in anti-microbial activity against bacteria is seen in addition to activity specific to fungal organisms and/or mold.... Agent: Allergan, Inc.

  
12/23/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100323949 - erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof: P

20100323950 - Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer: The present invention is directed to the use of the peptide compound Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100323951 - Antibacterial peptides active in systemic infections: Antimicrobial peptides of the formula are provided: X1—X2—PrO—X3—X4—PrO-Arg-Pro-Tyr-Leu-Pro-X5-Pro-Arg-Pro-Pro-Arg-Pro-Y, wherein X1 is a natural or non-natural amino acid having a free amino group or 1-amino-cyclohexyl carboxylic acid, X2 is Arg or N-methyl-Arg, X3 is Asp or GIu, X4 is Arg or Lys, X5 is Arg or Lys, and Y is Arg,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100323952 - Nucleoside analogs in combination therapy of herpes simplex infections: A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or peniclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.... Agent: Novartis Corporate Intellectual Property

20100323953 - Macrocyclic hepatitis c protease inhibitors: The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral... Agent: Schwegman, Lundberg & Woessner, P.A.

20100323954 - Chimeric polypeptides and uses thereof: The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20100323955 - Methods for treating obesity and obesity related diseases and disorders: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100323956 - Glucose-regulating polypeptides and methods of making and using same: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100323957 - Novel assay for inhibitors of egfr: The invention provides methods and compositions for screening for modulators of EGFR activity. In particular, an assay for such modulators is provided, which includes methods of screening for modulators using models of the three dimensional structure of EGFR kinase domains.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100323958 - Methods of use of biomaterial and injectable implant containing biomaterial: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for... Agent: King & Spalding

20100323959 - Methods of use of biomaterial and injectable implant containing biomaterial: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for... Agent: King & Spalding

20100323960 - Methods of use of biomaterial and injectable implant containing biomaterial: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for... Agent: King & Spalding

20100323961 - Surface eroding sutures: Barbed surgical sutures comprised of surface eroding materials are provided having increased degradation rates are provided.... Agent: Tyco Healthcare Group Lp D/b/a Covidien

20100323962 - Method of reduction of wrinkles on skin, darkening of hair and acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bfgf): The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected... Agent: The Webb Law Firm, P.C.

20100323963 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100323964 - New non-selective somatostatin analogues: The present invention relates to a new class of cyclopeptides of formula (1), reported here below, which are non-selective functional analogues of somatostatin.... Agent: Nixon & Vanderhye, PC

20100323965 - Thrombopoietin mimetics: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100323966 - Fviii peptides and their use in tolerising haemophiliacs: The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody... Agent: Morgan Lewis & Bockius LLP

20100323967 - Rna antagonist compounds for the modulation of mcl-1: Oligonucleotides directed against the Mcl-1 gene are developed for modulating the expression of Mcl-1 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Mcl-1. Methods of using these compounds for modulation of Mcl-1 expression and for the treatment of diseases associated with over expression of Mcl-1... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100323968 - Process of inhibiting cell death in injured cartilage: Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors.... Agent: The Scripps Research Institute

20100323969 - Compounds binding to p-selectin: The present invention relates to derivatives of compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such derivatives which comprise a peptide moiety or a functional equivalent of said peptide moiety and are represented by X(Ax)mA3A1A2A1Y. In addition, the invention relates to methods for preparing such... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100323970 - Sap variants and their use: Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore,... Agent: Ropes & Gray LLP Iprm - Floor 43

20100323971 - Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same: The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100323972 - Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy: The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.... Agent: Nixon & Vanderhye, PC

20100323973 - Conjugates containing hydrophilic spacer linkers: Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.... Agent: Barnes & Thornburg LLP

20100323974 - Inhibitors of parp activity and uses thereof: The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death... Agent: Harness, Dickey & Pierce, P.L.C

20100323975 - Therapeutic agent for cerebral ischemic injury: A therapeutic agent for cerebral ischemic injury contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient. The therapeutic agent for cerebral ischemic injury preferably has a dosage form as an injection for intravenous administration. The therapeutic agent for cerebral ischemic injury having a dosage form as... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100323976 - Novel anti-inflammatory pro-drugs: The present invention relates to compounds according to formula (I): wherein R2 is absent or a linking moiety and R3 is selected from the group consisting of anti- inflammatory agents and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising compounds of formula (I) and the use of these pharmaceutical compositions for... Agent: Foley And Lardner LLP Suite 500

20100323977 - Mucoadhesive nanoparticles for cancer treatment: The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and... Agent: Valauskas Corder LLC

20100323978 - Non-aqueous oil delivery system for ophthalmic drugs: The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that... Agent: Calvin Hanna

20100323979 - Methods and compositions for inhibiting proliferation of aneuploid cells: The present invention relates, in part, to the use of AMP kinase agonists to reduce or inhibit the proliferation of aneuploid cells. The invention is also directed to the use AMP kinase agonists to reduce or inhibit the proliferation of solid tumors characterized by aneuploidy in an individual.... Agent: Wolf Greenfield & Sacks, P.C.

20100324113 - Delivery method: The present invention relates, in general, to siRNA and, in particular, to a method of effecting targeted delivery of siRNAs and to compounds suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20100324116 - Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells: Provided herein are methods and compositions for killing tumor cells. In certain embodiments, compositions can promote apoptosis by down-regulating FAPP2 and PATZ1 products.... Agent: Themis Law

20100324112 - Genetic changes in atm and atr/chek1 as prognostic indicators in cancer: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to... Agent: Baker Botts L.L.P.

20100324117 - Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use: The present invention provides agents, compositions, constructs and methods for silencing HCV polynucleotides, as well as methods and compositions for treating or preventing HCV infection in a mammalian cell. In one aspect, the present invention provides an agent or composition comprising at least one double-stranded RNA effector molecule or complex.... Agent: David S. Resnick

20100324120 - Lipid formulation: e

20100324118 - Method for the promotion of angiogenesis, vascularization, or vascular repair or for the inhibition of tumor angiogenesis: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100324121 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100324114 - Methods and kits to detect hereditary angioedema type iii: The present invention relates to a method of diagnosing hereditary angioedema type III (HAE III) or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a hereditary angioedema type III or in a subject being suspected of being a carrier for... Agent: Birch Stewart Kolasch & Birch

20100324119 - Reducing irf4, dusp22, or flj43663 polypeptide expression: This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells... Agent: Fish & Richardson P.C. (tc)

20100324115 - Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy: Squamous cell carcinomas, such as squamous head and neck cancer, are treated with a combination of radio-therapy and a therapeutic agent that reduces the amount of hsp27 in the squamous cancer cells. In specific embodiments, the therapeutic agent that reduces the amount of hsp27 is an antisense oligonucleotide therapeutic agent.... Agent: Larson & Anderson, LLC

20100324124 - Compositions and methods relating to dna-based particles: The invention provides compositions and methods relating to delivery of agents in vivo or in vitro. More specifically, the invention provides nanoparticles synthesized from crosslinked nucleic acids, optionally having a lipid shell or coating, and may further comprise for example small molecule or high molecular weight compounds as therapeutic or... Agent: Wolf Greenfield & Sacks, P.C.

20100324123 - Glms riboswitches, structure-based compound design with glms riboswitches, and methods and compositions for use of and with glms riboswitches: The glmS riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the glmS riboswitch. The atomic structures of the glmS riboswitch can be used to design new compounds to stimulate, active, inhibit and/or inactivate riboswitches.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100324122 - Modulation of sglt2 expression: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.... Agent: Mcdermott Will & Emery LLP

20100324125 - Proteins derived from white spot syndrome virus and uses thereof: Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.... Agent: Intervet/schering-plough Animal Health

20100324126 - Syn3 compositions and methods: Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.... Agent: Townsend And Townsend And Crew, LLP

20100324127 - Treating neurodegenerative diseases with progranulin: The invention relates to methods and compositions for treating a neurodegenerative disease. More particularly, the present invention is directed to methods of treatment of neurodegenerative diseases using progranulin and progranulin polypeptides, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression.... Agent: Barnes & Thornburg LLP

20100323980 - Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100323981 - Treatment of statin side effects: In a preferred aspect the invention relates to a method of treatment of one or more side effects of statin therapy comprising administering to a subject in need of such treatment an effective amount of uridine, one of its biological precursors or a salt, ester, tautomer or analogue thereof either... Agent: Scully Scott Murphy & Presser, PC

20100323982 - Food composition for prodromal dementia patients: A composition comprising (a) one or more ω-3 fatty acids selected from DHA, DPA and EPA, (b) uridine or its equivalent, and (c) a methyl donor, useful in the treatment of a person having characteristics of a prodromal dementia patient. The characteristics include e.g. a level of more than 350... Agent: Foley And Lardner LLP Suite 500

20100323983 - Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof, and uses thereof: The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100323986 - Compositions and methods for modulation of vascular structure and/or function: The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as... Agent: Jones Day

20100323984 - Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding composition: e

20100323985 - Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same: The invention relates to a combination of hyaluronic acid and of at least one inhibitor of hyaluronic acid degradation, for use in particular in human dermatology or in reconstructive surgery.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100323987 - Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains: The invention relates to pharmaceutical combinations of retigabine and sodium channel inhibitors for treating, pains which are accompanied by an increase in muscle tone.... Agent: Mcdermott, Will & Emery LLP

20100323988 - Solid citrate and tartrate salts of dpp-iv inhibitors: This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolid acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100323989 - Pharmaceutical combinations useful for treating hcv: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.... Agent: Gilead Sciences Inc

20100323990 - Ship 1 modulator prodrugs: The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or... Agent: Seed Intellectual Property Law Group PLLC

20100323991 - Methods and products for treatment of diseases: The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further... Agent: Sheridan Ross PC

20100323992 - Pharmaceutical compositions for preventing and treating eye pathologies: The present invention relates to pharmacology, medicine, opthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies... Agent: Wilmerhale/boston

20100323993 - Uses of pentamidine and related compounds: Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid molecule, thereby treating the disease. In additional examples, the method comprises administration of... Agent: Klarquist Sparkman, LLP

20100323994 - Substituted imidazopyridazines useful as kinase inhibitors: t

20100323995 - Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present... Agent: Seed Intellectual Property Law Group PLLC

20100323996 - Means and methods of controlling commensales: wherein represents a single bond or double bond; R1 and R2 are independently selected from H, linear or branched C1 to C4 alkyl, linear or branched C1 to C4 alkenyl, linear or branched C1 to C4 alkinyl, and linear or branched C1 to C4 alkanoyl; R4 is selected from... Agent: Dt Ward, PC

20100324000 - Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptors: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the β2 adrenergic receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100324002 - Inhaled combination therapy: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.... Agent: Morgan Lewis & Bockius LLP

20100324001 - Novel methods for the treatment of inflammatory diseases: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula... Agent: King & Spalding

20100323997 - Novel uses: The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female... Agent: Hoxie & Associates LLC

20100323999 - Therapeutic molecules and methods-1: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of... Agent: King & Spalding

20100323998 - Topical composition containing the combination of mupirocin and beclomethasone: The present invention relates to a topical pharmaceutical composition comprising mupirocin and beclomethasone, a process for its preparation, its use in the treatment of infected dermatoses caused by bacteria susceptible to mupirocin and in the treatment of secondary bacterial infections in patients of steroid responsive dermatoses.... Agent: Glenmark Generics Inc.

20100324003 - Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the... Agent: Lucas & Mercanti, LLP

20100324004 - Method for treating diabetes: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.... Agent: Morgan Lewis & Bockius LLP

20100324005 - Method for treatment of diseases: The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering... Agent: Sheridan Ross PC

20100324006 - Hormone delivery system and method: A hormone delivery system and method are provided for administering bio identical human hormones using a combination of modalities for the treatment of human physiological conditions.... Agent: Law Office Of Mark Brown, LLC

20100324007 - Oral suspension of prednisolone acetate: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20100324008 - Psma binding ligand-linker conjugates and methods for using: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.... Agent: Barnes & Thornburg LLP

20100324010 - Amide compounds and use of the same: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100324011 - Azetidinyl diamides as monoacylglycerol lipase inhibitors: e

20100324012 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20100324013 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20100324014 - Azetidinyl diamides as monoacylglycerol lipase inhibitors:

20100324015 - Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors:

20100324016 - Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors:

20100324009 - Substituted sulfonamide compounds: Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.... Agent: Crowell & Moring LLP Intellectual Property Group

20100324017 - Acylguanidine derivative: An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100324018 - Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs: Pharmaceutical compositions having improved dissolution profiles for drugs therein is disclosed.... Agent: Wilmerhale / Rib-x Phramaceuticals

20100324019 - Use of riboflavin in the treatment of hypertension: The invention provides the use of riboflavin in the manufacture of a medicament for the treatment or prophylaxis of elevated blood pressure in a subject homozygous or heterozygous for the MTHFR C677T polymorphism. The invention also provides a pharmaceutical product for the treatment or prophylaxis of elevated blood pressure in... Agent: Licata & Tyrrell P.C.

20100324020 - Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors: The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R1-R5 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the... Agent: Pfizer Inc. Patent Department

20100324021 - (dihydro)imidazoiso[5,1-a]quinolines: e

20100324023 - Imidazobenzazepine cgrp receptor antagonists: Compounds of Formula I: I (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache.... Agent: Merck

20100324022 - Novel compounds: Compounds of formula (I), pharmaceutical compositions thereof, and methods for treatment using the same.... Agent: Glaxosmithkline Global Patents

20100324024 - Quinolizidinone m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent: Merck

20100324025 - Antibacterial agents: e

20100324026 - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4,... Agent: Merchant & Gould PC

20100324027 - Diazahomoadamantane derivatives and methods of use thereof: The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20100324028 - Novel compounds: wherein R1, R2, R3, R4 and R5 are defined as mentioned below, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100324029 - Therapeutic agents: The invention encompasses 2-[4-(imidazolyl)-phenyl]vinyl-heterocycle derivatives which selectively attenuate production of Abeta(1-42) and are useful in the treatment of Alzheimer's disease. Pharmaceutical compositions and methods of use are also encompassed.... Agent: Merck

20100324030 - 5-quinoline derivatives having an anti-bacterial activity: e

20100324031 - Aqueous pharmaceutical compositions containing borate-polyol complexes: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of... Agent: Alcon

20100324032 - Compounds and uses thereof in modulating amyloid beta: Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.... Agent: Foley & Lardner LLP

20100324033 - Oxadiazoanthracene compounds for the treatment of diabetes: v

20100324035 - Carboxamide compounds and their use: Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.... Agent: Goodwin Procter LLP Patent Administrator

20100324034 - Methods of using saha for treating hiv infection: The present invention relates to pharmaceutical preparations and methods for treating individuals infected with the human immunodeficiency virus (HIV). The pharmaceutical preparations comprise SAHA and another anti-viral agent. The invention also relates to methods for treating HIV infected patients, particularly patients with persistent, latent HIV infection of CD4+ T cells,... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20100324036 - Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100324037 - Pharmacokinetically improved compounds: e

20100324039 - Substituted indolealkanoic acids: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100324038 - Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer: The invention relates to compounds of formula I, wherein Ra is —C(O)OR1, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb... Agent: Millen, White, Zelano & Branigan, P.C.

20100324040 - 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer: The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.... Agent: Astrazeneca R&d Boston

20100324041 - Pyrrolopyridines as kinase inhibitors: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Viksnins Harris & Padys Pllp

20100324043 - Bicyclic and tricyclic compounds as kat ii inhibitors: m

20100324042 - Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors:

20100324044 - Metabotropic glutamate receptor isoxazole ligands and their use as potentiators:

20100324045 - Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih)1 (Ij), (Ik), (Il1-3). (Im1-3), (In1-3), (Io1-2), (Ip1-6), (Iq1-6), (Ir1-6) and (Is1-2), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation... Agent: Foley & Lardner LLP

20100324046 - 4-carboxybenzylamino derivatives as histone deacetylase inhibitors: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation... Agent: Merck

20100324048 - Disubstituted phthalazine hedgehog pathway antagonists: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100324047 - Raf kinase modulators and methods of use: The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A1, A2, A3, A4, A5, A6,... Agent: Amgen Inc.

20100324054 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent: Merck

20100324049 - Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor: wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl... Agent: Merck

20100324050 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100324051 - Novel compounds as opioid receptor modulators: s

20100324052 - Novel piperidine carboxylic acid amine derivatives: The invention relates to novel piperidine carboxylic acid amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of these novel compounds, pharmaceutical compositions comprising such compounds and especially the use of such compounds as... Agent: Hoxie & Associates LLC

20100324053 - Trisubstituted 1,2,4 triazoles: e

20100324055 - Solid states forms of varenicline salts and processes for preparation thereof: Salts and crystalline forms of several salts of Varenicline, i.e., Varenicline sulfate, Varenicline mesylate, and Varenicline fumarate, methods of preparing the solid states of Varenicline sulfate, Varenicline mesylate, and Varenicline fumarate, and processes for preparing Varenicline base from those Varenicline salts are provided.... Agent: Kenyon & Kenyon LLP

20100324058 - thrombin function compounds and pharmaceutical compositions based on them: This invention relates to new chemical compounds, application of these compound as thrombin inhibitors, and pharmaceutical compositions based on them, and can be used to treat and prevent thrombin-dependent thromboembolic events, and in research.... Agent: Knobbe Martens Olson & Bear LLP

20100324059 - Pharmaceutical compositions useful for treating hcv: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.... Agent: Gilead Sciences Inc

20100324060 - Pharmaceutical compositions useful for treating hcv: This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.... Agent: Gilead Sciences Inc

20100324056 - Biphenyl and phenyl-pyridine amides as p2x3 and p2x2/3 antagonists: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and... Agent: Grant D. Green Patent Law Department

20100324057 - Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient:

20100324061 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors:

20100324062 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Aurora-A, Axl, BMX, CHK2, c-RAF,... Agent: Genomics Institute Of The Novartis Research Foundation

20100324063 - Jak2 tyrosine kinase inhibition: The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.... Agent: Merck

20100324064 - Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders: The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and/or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob... Agent: Henry D. Coleman

20100324065 - Compounds and methods for development of ret modulators: Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing... Agent: Foley & Lardner LLP

20100324066 - Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same: This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2θ angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109° C. to about... Agent: Pfizer Inc

20100324067 - Tetracyclic dipyrano-coumarin compounds with anti-hiv and anti-mycobacterium tuberculosis activities: The present invention relates to tetracyclodipyrano-coumarin compounds of general formula (I), wherein the substituents are defined herein. These compounds exihibit dual biological activities of anti human immunodeficiency virus type 1 (HIV-1) infection and anti-Mycobacterium Tuberculosis (TB) infection.... Agent: Scully Scott Murphy & Presser, PC

20100324068 - Chemical compounds 785: Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally... Agent: Morgan Lewis & Bockius LLP

20100324070 - Indole, indazole and benzimidazole arylamides as p2x3 and p2x2/3 antagonists: i

20100324069 - Oxazolone and pyrrolidinone-substituted arylamides as p2x3 and p2x2/3 antagonists:

20100324071 - Novel glucokinase activators and methods of using same:

20100324072 - Pyrrolopyridine derivatives and their use as bace inhibitors: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100324073 - Pyrazolo [1,5-a] pyrimidine compounds: i

20100324074 - Protein kinase inhibitors: The present invention is directed to low molecular weight and orally bioavailable 3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the tyrosine kinase MET. The invention is also directed to compositions which comprise these compounds, and methods of... Agent: Tiger Pharmatech

20100324077 - Combinations of anilinopyrimidines and pyrion compounds: The present invention relates to combinations of an anilinopyrimidine, or a salt thereof, and a pyrion compound, or a salt thereof, which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of an anilinopyrimidine, or a salt thereof, selected from the group consisting... Agent: Philip S. Johnson Johnson & Johnson

20100324076 - Novel seh inhibitors and their use: wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100324075 - Therapeutic use of carboxyl ester lipase inhibitors: Compounds, pharmaceutical compositions, and their methods of use in raising serum HDL levels in subjects in need thereof are provided. Also provided are compounds, pharmaceutical compositions, and their methods of use in increasing reverse cholesterol transport in subjects in need thereof. Finally, methods for treating disease by raising serum HDL... Agent: Dinsmore & Shohl LLP

20100324078 - Crystalline forms of naltrexone methobromide: The present invention relates to novel crystalline forms of naltrexone methobromide including hydrated and solvated forms. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline forms of naltrexone methobromide, as well as methods of treating or preventing opioid... Agent: Mallinckrodt Inc.

20100324079 - Medicament for prophylaxis and treatment of alzheimer disease: A medicament effective for inhibiting onset of Alzheimer disease via intracellular aggregation mechanism is provided. A medicament for prophylaxis and treatment of Alzheimer disease comprising as an active ingredient apomorphine hydrochloride wherein cell death dependent upon intracellularly accumulated amyloid β proteins and/or p53 is inhibited; and/or wherein a level of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100324080 - Benzomorphan compounds: The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R1, R2, R3, R4, and R5 are as defined herein. These compounds are useful for treating constipation preferably constipation caused by mu-opioid agonist therapy.... Agent: Purdue Pharma, Lp

20100324083 - Combinations of organic compounds: e

20100324082 - Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one and related methods: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuroathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.... Agent: Foley And Lardner LLP Suite 500

20100324081 - Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient: a

20100324084 - Urea derivatives of tropane, their preparation and their therapeutic application:

20100324085 - Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.... Agent: Edwards Angell Palmer & Dodge LLP

20100324086 - Compounds and methods: A compound of formula (1) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder from pain, fever, inflammation and cancer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100324087 - Combined use of angiogenesis inhibitor and taxane: The problems of the present invention are to find a pharmaceutical composition and a method for treating cancer that exhibit excellent anti-tumor effect. Excellent anti-tumor effect is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with taxane.... Agent: Fish & Richardson P.C. (ny)

20100324088 - Fused pyridone m1 receptor positive allosteric modulators: The present invention is directed to fused pyridone compounds of formula (I) (I) that are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed... Agent: Merck

20100324089 - Anti-inflammatory composition: The invention relates to 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.... Agent: Virtual Law Partners LLP

20100324090 - Compositions of tolperisone: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.... Agent: King & Spalding LLP

20100324091 - Pyrazolone derivative: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a... Agent: Millen, White, Zelano & Branigan, P.C.

20100324093 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20100324092 - Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors: The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis... Agent: Merck

20100324094 - Conformationally restrained epothilone analogues as anti-leukemic agents: A method for synthesizing anti-leukemic epothilone analogues includes rigidifying a region between the macrolactone ring and the aromatic side-chain. The anti-leukemic compositions are non-naturally occurring epothilone analogue that are rigidified between the macrolactone ring and the aromatic side-chain.... Agent: Macmillan Sobanski & Todd, LLC

20100324095 - Pharmaceutical composition for inhibiting amyloid-beta protein accumulation: The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula... Agent: Birch Stewart Kolasch & Birch

20100324096 - Whitening agent and skin external preparation: wherein A is C1-6 alkyl, C5-6 cycloalkyl, benzyl, benzylcarbonyl, benzoyl, phenyl, pyridyl or pyrimidyl; Ra is H, C1-6 alkyl, or C2-6 alkenyl; “” represents a single bond or a double bond wherein n=1 or 2; Y is S or O; and R3 and R4 are each independently H, C1-6 alkyl,... Agent: Rankin, Hill & Clark LLP

20100324097 - Method of providing pirfenidone therapy to a patient: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used... Agent: Marshall, Gerstein & Borun LLP (intermune)

20100324098 - Sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP

20100324099 - Sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP

20100324100 - Sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP

20100324101 - Use of succinate dehydrogenase inhibitors for increasing the resistance of plants or parts of plants to abiotic stress: The invention relates to the use of succinate dehydrogenase inhibitors, in particular bixafen, for increasing the resistance of plants to abiotic stress factors, to a method for treating plants or parts of plants for increasing the resistance to abiotic stress factors and to a method for increasing the resistance of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100324102 - N-(3-pyridin-2-ylpropyl) benzamide derivatives as fungicides: e

20100324103 - Substituted enaminocarbonyl compounds:

20100324104 - 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein R1, R2,... Agent: Louis J. Wille Bristol-myers Squibb Company

20100324105 - Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100324106 - Compounds: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.... Agent: Glaxosmithkline Global Patents

20100324108 - Substituted isoindoline-1,3-dione derivatives: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions... Agent: Foley & Lardner LLP

20100324107 - Use of phthalimide and/or sulphonamide derivatives in the treatment of diseases which require reducing the tnf-alpha levels and an exogenous source of nitric oxide, phthalimide derivatives, sulphonamide derivatives, and a method for obtaining a sulphonami: The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of... Agent: The Nath Law Group

20100324109 - Composition for topical use: e

20100324110 - Self solidifying bioerodible barrier implant: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100324111 - Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and aspragine, and use thereof in the tratment of atopic dermatitis: The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100324128 - 9, 10-alpha, alpha-oh-taxane analogs and methods for production thereof: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group,... Agent: Morgan, Lewis & Bockius LLP

20100324129 - Ectoparasiticidal methods and formulations: Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof.... Agent: Eli Lilly & Company

20100324130 - Daa peripheral benzodiazepine receptor ligand for cancer imaging and treatment: Peripheral Benzodiazepine Receptor (PBR) is an attractive target for tumor imaging and treatment due to its up-regulation in numerous cancer cell types. DAA1 106 is a selective PBR ligand with high binding affinity. Aspects of the present invention are series of functionalized DAA1 106 analogs, which can be conjugated to... Agent: Stites & Harbison PLLC

20100324131 - Salvinorin derivatives and uses thereof: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.... Agent: Clark & Elbing LLP

20100324132 - Methods and compositions for promoting wound healing: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100324133 - Branched diepoxide compounds for the treatment of inflammatory disorders: The present invention provides certain diepoxide carbocyclic compounds wherein at least one carbocyclic ring carbon includes two non-epoxide substituents, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of inflammatory, autoimmune and hyper- or abnormally proliferative diseases and disorders.... Agent: King & Spalding

20100324134 - Medicament for preventive and/or therapeutic treatment of bowel disease: A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.... Agent: Greenblum & Bernstein, P.L.C

20100324135 - Disinfectant and method of making: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent.... Agent: Morrison & Foerster LLP

20100324136 - Oily base for a cosmetic and cosmetic comprising the same: The present invention provides an oily base for a cosmetic comprising an ester compound made from a multivalent alcohol and a fatty acid, characterized in that the ester compound is made from pentaerythritol and isononanoic acid and a molar ratio of a pentaerythritol residue and an isononanoic acid residue in... Agent: Jordan And Hamburg LLP

20100324137 - Lauric arginate as a contact antimicrobial: A surface disinfecting composition includes a combination of lauric arginate ethyl ester in combination with EDTA, octenyl succinic acid, octanoic acid, glycolic acid, lactic acid, or combinations thereof. The aqueous solution can be used to disinfect a wide variety of surfaces including food processing and storage equipment, vegetables and fruits,... Agent: Diversey, Inc.

20100324138 - Lipoxin a4 protection for retinal cells: Lipoxin A4 and its analogs have been found to be effective in inhibiting apoptosis of retinal pigment epithelial cells induced by oxidative stress. Thus lipoxin A4 and its analogs, for example, lipoxin A4 epimer 15, can be used to prevent and treat retinal diseases due to the progressive degeneration of... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100324139 - Process to pregabalin: The present invention relates to a novel method for the preparation of racemic pregabalin (1) or a single enantiomer thereof, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2).... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100324140 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20100324141 - High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction... Agent: Dechert LLP

20100324142 - Hydrocortisone derivatives and use thereof for therapeutic or cosmetic indications: The present invention relates to hydrocortisone derivatives, the method of production thereof and the therapeutic or cosmetic use thereof to combat hair loss or in the treatment of cutaneous physiopathologies.... Agent: Steinfl & Bruno

20100324143 - Bis(thio-hydrazide amide) salts for treatment of cancers: Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.... Agent: Foley & Lardner LLP

20100324145 - Crystalline acat inhibitor: The invention is directed to the Form A polymorph of N-benzyl-N′-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide and its use as a therapeutic/cosmetic agent.... Agent: Mcdermott Will & Emery

20100324144 - Therapy for hyperexcitability disorders: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.... Agent: Harness, Dickey, & Pierce, P.l.c

20100324146 - Dendrimeric enzyme inhibitors: The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions... Agent: Technology Law, PLLC

20100324147 - Arylcyclopropylamines and methods of use: Described herein are arylcyclopropylamine compounds that may inhibit enzymes comprising an amine oxidase domain, such as LSD1, MAO A and/or MAO B.... Agent: Michael Best & Friedrich LLP

20100324148 - Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100324149 - Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection: The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for... Agent: Medlen & Carroll, LLP

20100324150 - Hyperbranched polyglycerol for improving heart function: A method of improving heart function in a subject, the method comprising administering an effective amount of a hyperbranched polyglycerol to a subject. The improvement in heart function may include one or more of an increase in myocardial contractile function, reduced or absent fibrosis, an increase in mechanical efficiency of... Agent: Black Lowe & Graham, PLLC

20100324151 - Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear: The instant invention provides methods and compositions for the treatment of infection or infectious colonization of the eyelid and/or ocular surface for the treatment and prevention of ocular disorders and eyelid disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100324152 - Use of 1,2-decanediol for sebum reduction and cosmetic and/or dermatological formulations comprising 1,2-decanediol: The present invention relates to a use of 1,2-decanediol for reduction of the sebum concentration of the skin, a cosmetic and/or dermatological formulation for topical application comprising 1,2-decanediol, a method for reduction of the sebum concentration of the skin and a use of 1,2-decanediol and a method for assisting the... Agent: Connolly Bove Lodge & Hutz LLP

20100324153 - Anionic isosorbide derivatives and their use: wherein R represent a hydrogen atom, or an alkyl group with 6 to 22 C-atoms, or an acyl group, or a group X—SO3M, and M stands for a cation, a hydrogen atom or an alkali metal atom or an ammonium or an alkylammonium ion, and X represents an alkoxylated derivative... Agent: Dilworth & Barrese, LLP

20100324154 - Assessing susceptibility to vascular disorders: The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods... Agent: Townsend And Townsend And Crew, LLP

  
12/16/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100317562 - Dietary compositions: Compositions that include medical food emulsions are provided. The compositions can include a low pH solvent and amino acids wherein the amino acids are exclusive of at least one naturally occurring amino acid. Also provided are methods of making compositions that include medical food emulsions. Such medical food emulsions are... Agent: Fish & Richardson P.C. (bo)

20100317563 - Methods for modulating the proliferation and differentiation potential of stem cells and progenitor cells: Modulators of TRIM-NHL proteins and their use for modulating the proliferation and differentiation potential of stem cells and progenitor cells. Inhibitors of TRIM-NHL proteins, e.g. TRIM32, are useful for stem cell maintenance in vitro and in vivo. Assay methods for identifying TRIM-NHL protein modulators make use of the E3 ligase... Agent: Fulbright & Jaworski L.L.P.

20100317564 - Immunoregulatory peptides and methods of use: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media... Agent: Wilson, Sonsini, Goodrich & Rosati

20100317565 - Novel peptides and their use for the treatment of edema: The invention relates to novel peptides, which can be used for the production of pharmaceutical compositions. These pharmaceutical compositions can be used for the treatment of edema, in particular pulmonary edema.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100317566 - Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors... Agent: Andrews Kurth LLP

20100317567 - Diagnosing and protecting horses against papillomavirus: Compositions for conferring protection against Equus caballus papillomavirus (EcPV) and Bovine papillomavirus (BPV) infection in a subject are provided and include a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods for protecting a subject against EcPV and BPV infection... Agent: Stites & Harbison, PLLC

20100317568 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Paul D. Yasger Abbott Laboratories

20100317569 - Dig-5 insecticidal cry toxins: DIG-5 Cry toxins, polynucleotides encoding such toxins, use of such toxins to control pests, and transgenic plants that produce such toxins are disclosed.... Agent: Dow Agrosciences LLC

20100317570 - Composition and method for the treatment of diseases affected by a peptide receptor: The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor.... Agent: Chalker Flores, LLP

20100317571 - Methods for reducing cd36 expression: The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about... Agent: Foley & Lardner LLP

20100317572 - Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of Formula I and an anti-obesity compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating obesity or an obesity associated disease.... Agent: Birch Stewart Kolasch & Birch

20100317573 - Pediatric fiber mixture: The present invention relates to a liquid nutritional composition for paediatric patients comprising beta-galacto-oligosaccharides, fructan, non-digestible alpha-glucan and hemicellulose.... Agent: Foley And Lardner LLP Suite 500

20100317574 - Diketopiperazine microparticles with defined isomer contents: Disclosed herein are fumaryl diketopiperazine (FDKP) compositions and microparticles having a specific trans isomer content of about 45% to about 65%. The FDKP microparticles can comprise a drug such as an endocrine hormone, including, peptide, including, insulin, glucagon, parathyroid hormones and the like and can be used to make a... Agent: K&l Gates LLP

20100317575 - Pharmaceutical composition comprising a pyrazole-o-glucoside derivative: The invention relates to a pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100317576 - Methods of enhancing diabetes resolution: Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100317577 - Methods and compositions for inhibiting cell death or enhacing cell proliferation: The present invention provides compositions and methods that enhance cell survival. Such compositions feature chimeric polypeptides that include at least a GM-CSF receptor ligand and an anti-apoptotic moiety (e.g., a Bcl-2 protein family member). In one embodiment, the chimeric polypeptide is a GM-CSF-Bcl-xL chimeric polypeptide. The invention further includes methods... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100317578 - Method of protecting against stroke through the use of a delta opioid peptide: The subject invention pertains to uses of delta opioid peptides and salts thereof for promoting neurogenesis and to pharmaceutical compositions containing such peptides and salts as active ingredients. Specifically exemplified herein is [D-Ala2,D-Leu5]enkephalin (DADLE) and salts thereof. The peptides of the present invention upregulate glial cell-derived neurotrophic factor (GDNF) in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100317579 - Controlled release formulations of octreotide: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a... Agent: Foley And Lardner LLP Suite 500

20100317580 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100317581 - Ipamorelin diacetate injection and infusion solutions: e

20100317582 - Novel cyclic hydrocarbon compounds for the treatment of diseases: The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of... Agent: Birch Stewart Kolasch & Birch

20100317583 - Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa): Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally... Agent: Cooley LLP Attn: Patent Group

20100317584 - Pharmaceutical composition, package and method for rapidly reducing the uric acid in blood: The present invention relates to a pharmaceutical composition for rapidly reducing the uric acid level in blood in a subject, which comprises anserine in an amount of greater than 50 mg to about 600 mg. The present invention further relates to a package comprising the pharmaceutical composition comprising anserine, and... Agent: Ladas & Parry LLP

20100317585 - Long-acting coagulation factors and methods of producing same: Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.... Agent: Pearl Cohen Zedek Latzer, LLP

20100317586 - Method for topical treatment of eye disease and composition and device for said treatment: A method for the prevention or treatment of an eye disease, which includes topically applying to a patient in need of the treatment an aqueous ophthalmic composition which includes N-acetylcarnosine, a N-acetylcarnosine derivative or a pharmacologically acceptable salt of N-acetylcarnosine, in combination with an amount of a cellulose compound or... Agent: James C. Lydon

20100317587 - Injectable bone regeneration gel containing bone formation enhancing peptide: The present invention relates to an injectable bone regeneration material containing a bone formation enhancing peptide, and more particularly, to an injectable bone regeneration material, in which a bone formation enhancing peptide essentially containing one and more amino acid sequences among SEQ ID NO: 1 to SEQ ID NO: 28... Agent: Edwards Angell Palmer & Dodge LLP

20100317588 - Compositions comprising fibrous polypeptides and polysaccharides: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100317589 - Compositions and methods for treatment of multiple sclerosis: Disclosed are novel compositions and methods for the treatment of Multiple Sclerosis (MS), and in particular immunostimulatory compositions comprising muramyl dipeptide microparticles for use, e.g., in the treatment of MS.... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20100317590 - Regulation of skin characteristics by dickkopf1 (dkk1): The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation,... Agent: Klarquist Sparkman, LLP (ott-nih)

20100317591 - Use of lipid conjugates in the treatment of diseases: This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or... Agent: Pearl Cohen Zedek Latzer, LLP

20100317592 - Chemokine-binding protein and methods of use: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by... Agent: Knobbe Martens Olson & Bear LLP

20100317593 - 2,3-dihydro-1h-indene compounds: Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers.... Agent: Astrazeneca R&d Boston

20100317594 - Methods for treating breast cancer using nrif3 related molecules: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to... Agent: Fish & Richardson P.C. (ny)

20100317595 - Compositions for enhancing nail growth: The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the... Agent: Allergan, Inc.

20100317597 - Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders: Medical foods containing glycomacroprotein and additional supplemented amounts of arginine, leucine, and optionally other amino acids, such as tyrosine, are disclosed. The medical foods can be used to provide the complete protein requirements for patients having metabolic disorders such as phenylketonuria.... Agent: Quarles & Brady LLP

20100317596 - Serum amyloid p derivatives and their preparation and use: One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP... Agent: Ropes & Gray LLP Iprm - Floor 43

20100317598 - Isolated brca1 peptides and method of use: The invention provides isolated peptides of a BRCA1 domain, which bind to p53 cognate DNA and stimulate transcription activities and cancer cell apoptosis. Nucleic acids encoding the peptides, and methods of expression thereof, are also provided. The invention provides pharmaceutical compositions, and methods of use thereof, for treating breast and... Agent: Sutherland Asbill & Brennan LLP

20100317599 - Process for the production of a peptide: The present invention describes a polypeptide, comprising at least one repeat domain, further comprising a recombinant peptide of interest. The present invention further describes a process for the production of a recombinant peptide of interest. The invention further describes the use of a repeat protein for the production of a... Agent: Nixon & Vanderhye, PC

20100317601 - Casein derived peptides and uses thereof: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and... Agent: Dr. D. Graeser Ltd.

20100317600 - Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100317602 - Nutritive compositions and methods of using same: The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from... Agent: Wilson, Sonsini, Goodrich & Rosati

20100317604 - Forsythiaside injection preparation and preparative method thereof: The present invention discloses a Forsythiaside injection preparation and preparative method thereof. This injection preparation is prepared by Forsythiaside and pharmaceutical adjuvant.... Agent: Birch Stewart Kolasch & Birch

20100317603 - Treatment of cancer and inflammatory disorder: Disclosed are extracts, compositions, and methods for treating cancer and inflammatory disorders. Also disclosed are methods for preparing extracts or compounds for treating the disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100317605 - The use of epimedium flavones and effective components thereof for the preparation of medicaments of promoting proliferations and differentiations of nerve cells: The use of epimedium flavones and/or icariins for the preparation of medicaments of promoting proliferations and/or differentiations of nerve cells, is disclosed.... Agent: Kenyon & Kenyon LLP

20100317606 - Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100317607 - Use of compounds for preparing anti-tuberculosis agents: Compounds of a compound of compound of general formula (I) wherein X1, X2, A, R1R2, R3 and R4 are as defined herein; are useful as anti-mycobacterial agents, especially agents for the treatment of tuberculosis.... Agent: Seed Intellectual Property Law Group PLLC

20100317608 - Dithiol compounds, derivatives, and uses therefor: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.... Agent: Townsend And Townsend And Crew, LLP

20100317609 - Method of producing hydroxyalkyl starch derivatives: The present invention relates to methods of producing hydroxyalkyl starch (HAS) derivatives having a structure according to formula (I) comprising reacting HAS of formula (I) at its optionally oxidized reducing end or a HAS derivative, obtainable by reacting HAS of formula (I) at its optionally oxidized reducing end with a... Agent: Fish & Richardson P.C. (tc)

20100317719 - Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.... Agent: Goodwin Procter LLP Patent Administrator

20100317714 - Complex molecule interfering the expression of target genes and its preparing methods: The present invention provides a complex molecule interfering the expression of target genes and the methods for preparing the complex molecule, wherein the complex molecule contains two siRNA strands X1 and X2 having at least 80% complementarity, the 5′ end of X1 and 3′ end of X2 are linked through... Agent: Volpe And Koenig, P.C.

20100317720 - Methods and compositions for the treatment of intestinal conditions: Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.... Agent: King & Spalding

20100317715 - Methods for treating neuropsychiatric conditions: Provided herein are compositions and methods for treating a subject suffering from Fragile X syndrome, autism, Down's syndrome, mental retardation, or a neuropsychiatric condition (e.g., schizophrenia). The methods include systemic administration of a a therapeutically effective amount of a PAK inhibitor in combination with a Group I mGluR antagonist (e.g.,... Agent: Wilson, Sonsini, Goodrich & Rosati

20100317713 - Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair: A family of microRNAs, called the miR-15 family, which includes miR-195, are shown to be up-regulated during pathological cardiac remodeling and repress the expression of mRNAs required for cell proliferation and survival, with consequent loss of cardiomyocytes. Strategies to block expression of the miR-15 family in the heart as a... Agent: Cooley LLP Attn: Patent Group

20100317718 - Modulation of hif1 beta expression: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20100317717 - Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other... Agent: Merck C/o Sirna Therapeutics, Inc.

20100317716 - Rna interference mediated inhibition of tnf and tnf receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways... Agent: Merck C/o Sirna Therapeutics, Inc.

20100317721 - Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.... Agent: Bozicevic, Field & Francis LLP

20100317724 - Method for searching for homing endonucleases, their genes and their targets: A computer implemented method for generating nucleotide sequences containing candidate homing endonuclease genes (HEGs). A search is performed in a database stored on a storage medium of nucleotide sequences for amino acid sequences having a subsequence having a homology level with the translation of a subsequence of one or more... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100317722 - Nucleic acid sequences comprising nf-kb binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders: The invention relates to nucleic acid sequences comprising NF-κB binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-κB binding... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20100317723 - Nucleolin specific aptamer and use thereof: Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.... Agent: LexyoumeIPGroup, PLLC

20100317610 - Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.... Agent: Macmillan Sobanski & Todd, LLC

20100317611 - Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the... Agent: Dechert LLP

20100317612 - Method of obtaining of 4-n-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-n-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition: The subjects of the present invention are the method of preparation of 4-furfurylcytosine and/or its derivatives, its use in the manufacture of anti-aging compositions and an anti-aging composition. As 4-furfurylcytosine and/or its derivatives possesses a series of biological properties it might be use as a composition having excellent anti-aging effect... Agent: Walker & Jocke, L.p.a.

20100317613 - Activity enhancer for detoxifying enzyme: It is intended to provide a drug, a food or a feed which has an effect of enhancing the activity of a second-phase detoxifying enzyme and an effect of increasing intracellular glutathione content.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100317616 - Alkylated semi-synthetic glycosaminoglycan ethers, and methods of making and using thereof: Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases... Agent: Ted W. Whitlock Registered Patent Attorney, P.A.

20100317614 - Compositions and methods for pest control: Provided herein are compositions and kits comprising carbohydrate-based inhibitors that bind GNBP and/or inhibit β(1,3)-glucanase activity. Also provided are methods of using such inhibitors to protect against or treat pest infestation, as are compositions and kits comprising subparts of the carbohydrate-based inhibitors.... Agent: Wolf Greenfield & Sacks, P.C.

20100317615 - Method of enhancing ocular penetration of a drug in an eyedrop: A method of enhancing ocular penetration of a drug in an eyedrop by administering to an eye, an eyedrop containing, particulate agar having a weight-average molecular weight of from 5,000 to 1,200,000, the particulate agar being obtained by dissolving agar into an aqueous solution by heating and then cooling the... Agent: Holtz, Holtz, Goodman & Chick PC

20100317617 - Silver nanoparticles as anti-microbial: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle... Agent: Schmeiser, Olsen & Watts

20100317618 - 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of novel 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100317620 - N-phenylimidazo[1,2-a]pyridine-2-carboxamide compounds, preparation and therapeutic use thereof: e

20100317619 - Selective agents for pain suppression: In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present... Agent: Boyle Fredrickson S.c.

20100317621 - Beta-lactamase inhibitors: Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100317622 - Producing method of phospholipids including long-chain polyunsaturated fatty acids as constituents, and use of such phospholipids: The present invention provides a method of efficiently and stably producing LCPUFA-PL. Specifically, the invention provides a method for producing phospholipids that contain LCPUFA as a constituent (LCPUFA-PL), wherein lipid producing cells producing lipids that contain long-chain polyunsaturated fatty acids (LCPUFA) are used as a starting material, the method including... Agent: Drinker Biddle & Reath (dc)

20100317623 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck

20100317624 - Heterocyclic urea derivatives and methods of use thereof: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20100317625 - Novel sulfonamidomethylphosphonate inhibitors of beta-lactamase: This invention provides novel β-lactamase inhibitors of the aryl- and heteroaryl-sulfonamidomethylphosphonate monoester class. The compounds inhibit three classes of β-lactamases and synergize the antibacterial effects of β-lactam antibiotics (e.g., imipenem and ceftazimdime) against those micro-organisms normally resistant to the β-lactam antibiotics as a result of the presence of the β-lactamases.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100317626 - The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd: The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD).... Agent: Pepper Hamilton LLP

20100317627 - Treatment of hcv disorders: S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).... Agent: Novartis Corporate Intellectual Property

20100317628 - Microrna modulators and method for identifying and using the same: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent increases or decreases the expression of... Agent: Licata & Tyrrell P.C.

20100317629 - Dissolvable pharmaceutical implant: A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some... Agent: Medtronic, Inc.

20100317630 - Novel heterocyclic compounds as mglu5 antagonists: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering... Agent: John Russell Uren

20100317632 - 17-(1'propenyl)-17-3'-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative: The invention relates to 17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the meanings stated in Claim 1, and their solvates, hydrates and salts, including all stereoisomers of these compounds. The invention further relates to the... Agent: Millen, White, Zelano & Branigan, P.C.

20100317631 - Gel composition and transcrotal application of a composition for the treatment of hypogonadism: The present invention relates to a gel composition on alcoholic basis, comprising at least one androgenic steroid and at least one C3-C4 diol as enhancer, as well as the use of a composition comprising at least one androgenic steroid on the scrotum for the treatment and/or prophylaxis of hypogonadism.... Agent: Leydig Voit & Mayer, Ltd

20100317633 - Hexahydro-cyclooctyl pyrazole cannabinoid modulators: e

20100317634 - Piperidyl-propane-thiol ccr3 modulators: One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R1, R2, R3 and R4 are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100317636 - Reducing the risk of chronic lung disease in infants: Described herein is a method for reducing the risk of chronic lung disease in an infant suffering from respiratory distress syndrome by administering to the infant a combination of a corticosteroid having a high local to systemic anti-inflammatory activity (e.g., budesonide) and a lung surfactant.... Agent: Fish & Richardson P.C. (bo)

20100317635 - Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators: s

20100317637 - Anti-hepatitis c composition and method for preparing drug for inhibiting hepatitis c viruses or treating hepatitis c: where R1 comprises H or OAc and R2 comprises H or COCH(CH3)2; and a pharmaceutically acceptable carrier or salt, and the anti-hepatitis C composition is used for inhibiting hepatitis C virus or treating hepatitis C. The invention also provides a method for treating hepatitis C and a method for preparing... Agent: Pai Patent & Trademark Law Firm

20100317638 - Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally related pentacylic steroids: Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused... Agent: Senniger Powers LLP (wshu)

20100317639 - Medicament based on a monoester of steroids with long chain fatty acids: A monoester of a family of steroids with a C16-C24 fatty acid for use as a medicament is disclosed. Particularly the monoester of 5α-androstan-3α,17β-diol with a C16-C24 fatty acid is disclosed, such as preferably linoleic acid in all its isomeric forms. The medicament is capable to reduce the accumulation of... Agent: Thomas E. Spath Abelman, Frayne & Schwab

20100317640 - Antimicrobial zinc pyrithione composition and method: The present invention relates to the field of antimicrobial formulations, and more specifically, to an antimicrobial formulation comprising zinc pyrithione in a stabilized dispersion.... Agent: Microban Products Company

20100317643 - Janus kinase inhibitor compounds and methods: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof... Agent: Genentech, Inc.

20100317642 - Pharmaceutical composition of orlistat: A stable pharmaceutical composition comprising dispersion blend comprising 20 to 60% by weight of orlistat and 40% to 80% by weight of water soluble polymer carrier selected from hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or hydroxypropyl methylcellulose and the like.... Agent: Merchant & Gould PC

20100317646 - Compounds: s

20100317647 - Novel cyclopentane derivatives:

20100317649 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100317645 - Substituted diazepine sulfonamides as bombesin receptor subtype-1 modulators: Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent: Merck

20100317648 - Therapeutic compounds: wherein R1-R6, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100317644 - Substituted sulfonamide compounds: Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.... Agent: Crowell & Moring LLP Intellectual Property Group

20100317641 - Thiazoles and pyrazoles useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Inc.

20100317650 - Imidazopyridine derivatives useful as inos inhibitors: e

20100317651 - Pyrazinooxazepine derivatives:

20100317652 - Compounds useful in therapy: or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y′ are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated,... Agent: Pfizer Inc. Patent Department

20100317653 - Oxadiazole derivatives as dgat inhibitors:

20100317654 - 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20100317655 - Sulfonamide inhibitors of carbonic anhydrase: The present invention relates to new sulfonamide inhibitors of carbonic anhydrase activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group, LLC

20100317656 - Imidazo[1,2-a]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics: e

20100317657 - 1h-imidazo[4,5-c]quinolinone derivatives: The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a... Agent: Novartis Institutes For Biomedical Research, Inc.

20100317658 - 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses: A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.... Agent: Hunton & Williams LLP Intellectual Property Department

20100317659 - Jak kinase modulating compounds and methods of use thereof: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.... Agent: Jones Day

20100317660 - Mediators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize... Agent: Millen, White, Zelano & Branigan, P.C.

20100317662 - Metabotropic glutamate receptor isoxazole ligands and their use as potentiators - 286: e

20100317661 - Small molecule inhibitors of mdm2 and the uses thereof: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).... Agent: Casimir Jones, S.c.

20100317663 - Anilinopyridines as inhibitors of fak: e

20100317664 - Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein: Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof... Agent: Lexicon Pharmaceuticals, Inc.

20100317665 - Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death: A novel class of pyridazine compositions and related methods of use.... Agent: Millen, White, Zelano & Branigan, P.C.

20100317667 - 1-aryl-or 1-heteroaryl-pyrido[b]indoles and uses thereof: Provided herein are 1-aryl or 1-heteroarylsubstituted phenanthrene diketo acid compounds. These compounds comprise a β-carboline ring structure substituted at C1 with an aryl or heteroaryl moiety and individually substituted at C3-C8 and N9 with a C1-C4 alkyl, a C1-C4 alkoxy, a C1-C4 alkoxyphenyl, halogen, thiol, alkylthiol, sulfonyl, sulfomainde, amide, substituted... Agent: Benjamin Adler Adler & Associates

20100317666 - Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss: The present invention relates to methods for treating a subject suffering from tinnitus, hearing loss, or tinnitus and hearing loss comprising administering to the subject an effective amount of an NK1 receptor antagonist alone, or in combination with an effective amount of a selective serotonin reuptake inhibitor. Compositions and pharmaceutical... Agent: Glaxosmithkline Global Patents

20100317668 - Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use: wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease... Agent: Amgen Inc.

20100317669 - Novel substituted piperidyl-propane-thiols: One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R1, R2, R3 and D are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100317670 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, Z1, Z2, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Pyridylene Compound”); compositions comprising an effective amount of a Pyridylene Compound; and methods for treating or preventing pain or other conditions in an animal comprising administering to an animal in... Agent: Dechert LLP

20100317671 - Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line: A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP... Agent: Volpe And Koenig, P.C.

20100317672 - Monomaleate monohydrate salt of a 5ht1a receptor antagonist: The present invention relates to a monomaleate monohydrate salt of 7-methyl-6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4,5-dihydroimidazo[1,5-a]quinoline-3-carboxamide, uses of the salt as a medicament in the treatment of sexual dysfunction and pharmaceutical compositions and dosage forms comprising the salt.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100317674 - Metabotropic glutamate-receptor-potentiating isoindolones: e

20100317673 - N-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application:

20100317675 - 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof:

20100317676 - Fused heterocyclic compounds, and compositions and uses thereof: where A, B, L, N, R1, R3, R4′, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and... Agent: Klauber & Jackson

20100317677 - Methods of treating a microbial infection by modulating rnase-l expression and/or activity: The invention relates to methods and compositions for treating a microbial infection. In the present invention, RNase-L activity has been shown to play an integral role in innate immunity and for defense against invading microbes. The present invention is drawn to exploiting the role of RNase-L in innate immunity for... Agent: Morgan Lewis & Bockius LLP

20100317678 - Hydroxamates as inhibitors of histone deacetylase: wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or... Agent: Banner & Witcoff, Ltd.

20100317680 - Pyrimidine inhibitors of kinases: e

20100317679 - Substituted aryl-fused spirocyclic amines: Substituted Aryl-fused Spirocyclic Amines of the formula (I): are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in... Agent: Cantor Colburn LLP

20100317681 - Modulation of systemic exposure to rifaximin: The present invention relates to the effect of hepatic insufficiency on the pharmacokinetics of rifaximin. Also provided are methods of determining an appropriate dose of rifaximin for a subject suffering from hepatic insufficiency. In addition, methods of treatment are provided subjects having or susceptible to hepatic insufficiency to be treated... Agent: Edwards Angell Palmer & Dodge LLP

20100317683 - Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer: The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer.... Agent: Mallinckrodt Inc.

20100317682 - Single dosage unit including opioid and methylnaltrexone or methylnaltrexone salt: The use of methylnaltrexone bromide in combination and in one dosage unit, with any opioid drug in order to prevent the constipation which can be associated with opioids.... Agent: Antonelli, Terry, Stout & Kraus, LLP

20100317684 - Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer: Amide and carbamate derivatives N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds in modulating the immune system, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20100317687 - 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof: i

20100317688 - 2-heteroaroylimidazol[1,2-a]pyridine derivatives, preparation and therapeutic use thereof:

20100317686 - N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof:

20100317685 - N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application:

20100317689 - Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety: The compounds of formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability... Agent: Gabor L Szekeres Law Offices Of Gabor L Szekeres

20100317690 - Treatment of protein folding disorders: Described are various compounds and methods for the treatment of disorders arising from aberrant protein folding, including in particular lysosomal storage diseases. In particular, polyhydroxylated alkaloids and imino sugars which are pharmacoperones of an enzyme and which do not bind to a catalytic site of said enzyme are described.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100317691 - Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2: R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl,... Agent: Wilkinson & Grist

20100317693 - 3,8-diaminotetrahydroquinoline derivative: A 3,8-diaminotetrahydroquinoline derivative represented by formula (1a) (wherein X represents CH2, C═O, CH—OR, CH—SR, or CH—NRR′; m is a number of 1 or 2; Ar represents a phenyl group, a naphthyl group, a 5-membered or 6-membered aromatic heterocyclic group having one or two elements selected from S, N, and O,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100317692 - Quinolone m1 receptor positive allosteric modulators: which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed... Agent: Merck

20100317694 - Solid pharmaceutical composition comprising donepezil hydrochloride: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.... Agent: Swanson & Bratschun, L.L.C.

20100317695 - Gel composition for treating mycosis: The gel composition of the present invention is excellent in permeation of KP-103 into a target site and also excellent in permeation into the nail. Thus, the gel composition of the present invention allows the drug to be directly and rapidly absorbed and permeated into a target site in a... Agent: Sughrue Mion, PLLC

20100317696 - Iminosugars and methods of treating bunyaviral and togaviral diseases: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.... Agent: Foley And Lardner LLP Suite 500

20100317697 - Renin inhibitors: Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100317698 - Polysubstituted pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them: s

20100317699 - Use of hedgehog agonists in the treatment of musculoskeletal-related disorders: The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize Sonic Hedgehog (shh), and thereby, the Hedgehog signaling pathway. Said agonizing agents include, e.g., the compounds of the... Agent: Novartis Institutes For Biomedical Research, Inc.

20100317700 - Pesticidal compositions: To provide a formulation composition which improves the controlling effect of an anthranilamide compound against pests. A pesticide composition which is a concentrated composition containing an anthranilamide compound as a pesticidal active ingredient, a dispersant and a hydrophilic organic solvent, characterized in that when the composition is diluted with water,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100317701 - Heterocyclic inhibitors of necroptosis: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features... Agent: Clark & Elbing LLP

20100317702 - Crystalline form of febuxostat: New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout.... Agent: Merchant & Gould PC

20100317703 - Method for inhibiting brassinin oxidase: The present disclosure relates to a method for inhibiting brassinin oxidase comprising treating a pathogen that is producing BO with an effective amount of selected Paldoxin compounds.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100317704 - Spiro-condensed imidazolone derivatives inhibiting the glycine transporter: wherein the groups are as defined in the specification. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100317705 - Oligomer-dantrolene conjugates and related compounds: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20100317706 - Hnf4alpha modulators and methods of use: Disclosed are methods and compositions relating to modulators, such as agonists and antagonists, of HNF4α.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100317707 - Oligomer-nitroimidazole anti-infective conjugates: The invention provides (among other things) small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer.... Agent: Nektar Therapeutics

20100317708 - Carcinoma diagnosis and treatment, based on odc1 genotype: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the... Agent: Fulbright & Jaworski L.L.P.

20100317709 - Sphingosine-1-phosphate (s1p) receptor compounds: The invention relates to compounds, in particular 2-amino-3,4,5,-trisubstituted thiophenes, pharmaceutical compositions containing them and the uses of said compounds and compositions for diseases related to sphingosine-1-phosphate (S1P) receptors, predominantly S1P3 receptors. The diseases include cardiovascular diseases, atherosclerosis, cancer, pulmonary oedema, autoimmune disorders and Adult Respiratory Distress Syndrome.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100317710 - 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium... Agent: Darby & Darby P.C.

20100317711 - Stem-like cells and method for reprogramming adult mammalian somatic cells: A new use is provided for small molecule inhibitors of Oct4 and Sox 2 as a cellular reprogramming agent and a method of reprogramming adult mammalian somatic cells into stem-like cells is provided, using small molecule inhibitors of Oct4 and Sox 2 without the need of any material derived from... Agent: Global Patent Group - Glm

20100317712 - Estrogen agonists/antagonists for preventing breast cancer: n

20100317725 - Choline esters: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.... Agent: Townsend And Townsend And Crew, LLP

20100317726 - Slco1b3 genotype: The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100317728 - Dietary and pharmaceutical compositions comprising a sage extract containing a mixture of tricyclic diterpenes and their derivatives and their uses: The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic... Agent: Nixon & Vanderhye, PC

20100317727 - Rosemary extracts, dietary and pharmaceutical compostions containing them and their uses: The present invention refers to rosemary extracts for use as medicament for the treatment of a disorder connected to reduced neurotransmission, as well as to dietary and pharmaceutical compositions containing such rosemary extracts and their uses.... Agent: Nixon & Vanderhye, PC

20100317731 - Hyperhidrosis treatment: Disclosed is a medicinal composition and method of use conspiring topiramate for treating drug-induced excessive sweating (hyperhidrosis). As a further embodiment of this invention, topiramate may be administered along with another medicament that causes excessive sweating to prevent such excessive sweating. As still a further embodiment of this invention, topiramate... Agent: Sam Rosen, Esquire Hodes, Pessin & Katz, P.A.

20100317732 - Method of inhibiting abcg2 and other treatment methods: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal.... Agent: Leydig, Voit & Mayer, Ltd.

20100317729 - New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin: The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably... Agent: Wolf Greenfield & Sacks, P.C.

20100317730 - Treatment for menopausal and perimenopausal vasomotor symptons: Disclosed is a medicinal composition and method of use comprising topiramate for treating hot flashes and excessive sweating known as vasomotor symptoms related to perimenopausal or menopausal symptoms and in a still further embodiment of the invention topiramate and the medicine for treating menopause and perimenopause are provided in a... Agent: Sam Rosen, Esquire Hodes, Pessin & Katz, P.A.

20100317733 - Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils: It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic,... Agent: Weaver Austin Villeneuve & Sampson LLP

20100317734 - Free fatty acid blends and use thereof: An antimicrobial composition comprising a blend of two or more natural free fatty acids derivable from milk serum lipid, the free fatty acids being selected from: butyric (C4); caproic (C6); caprylic (C8); capric (C10); lauric (C12); myristic (C14); palmitic (C 16): palmitoleic 5 (C16:1); stearic (C1 8); oleic (C18:1); linoleic... Agent: Jacobson Holman PLLC

20100317735 - High eicosapentaenoic acid oils from improved optimized strains of yarrowia lipolytica: Described are engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing an oil comprising greater than 50 weight percent of eicosapentaenoic acid [“EPA”], an ω-3 polyunsaturated fatty acid, measured as a weight percent of total fatty acids [“% TFAs”] and having a ratio of at least 3.1 of... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100317736 - Composition of the skin external application or the food for accelerating proline recycling by containing theanine: Disclosed herein is a composition for promoting proline recycling, and more particularly, to a composition for external application to skin or cosmetic food comprising theanine as an active ingredient for promoting expression or activity of prolidase, which is an enzyme to promote proline recycling, thereby increasing collagen synthesis and restoring... Agent: Nixon & Vanderhye, PC

20100317737 - Topical delivery of l-arginine to cause beneficial effects: The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The... Agent: Wolf Greenfield & Sacks, P.C.

20100317738 - Compositions and methods for treating conditions associated with neuronal dysfunction: The present invention relates to compositions and methods for the treating and empirically investigating conditions associated with neuronal dysfunction (e.g., chronic pain, epileptic neuronal activity). In particular, the present invention provides compositions and methods for using flufenamic acid in the treatment and empirical investigation of conditions associated with neuronal dysfunction... Agent: Towsend And Towsend And Crew LLP

20100317739 - Histone deacetylase inhibitors: Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e.g., to treat cancer, are provided.... Agent: Mckeon Meunier Carlin & Curfman LLC

20100317740 - Method for predicting response to tamoxifen: This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from... Agent: The Law Office 0f Geoffrey M. Karny

20100317741 - Method for treating septic shock or endotoxemia: The invention provides a method for treating septic shock or endotoxemia, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising formula I, II, III or IV and their salt, ester or solvate thereof.... Agent: Wpat, PC Intellectual Property Attorneys

20100317742 - Compositions and methods for controlling a honey bee parasitic mite: As described below, the present invention provides methods and compositions for controlling a honey bee parasitic mite. In addition, the invention features compositions useful for the treatment or prevention of a parasitic mite infestation in a honey bee hive.... Agent: Edwards Angell Palmer & Dodge LLP

20100317743 - Methods and compositions for use with gel dispensers: A method is provided for reducing the frequency of mis-directed output of hydroalcoholic gel from a dispenser. A method of reducing the formation of coagulated gel deposits, and dispensable hydroalcoholic gel compositions are also provided.... Agent: Renner Kenner Greive Bobak Taylor & Weber

20100317744 - Brominated nitroalkanol compositions and their use as biocides: m

20100317745 - Bioresorbable polymers: A bioresorbable polymer is obtained by reacting together (a) a prepolymer comprising co-polymerised units of a caprolactone and poly(alkylene oxide) moieties; (b) a polycaprolactone diol comprising co-polymerised units of a caprolactone and a C2-C6 diol; and (c) a diisocyanate. The polymer may be loaded with a pharmaceutically active agent to... Agent: Law Office Of John K. Pike, PLLC

20100317746 - Improved isomalt-containing tablets and methods for the production thereof: The invention relates to improved isomalt-containing tablets and to methods for the production thereof.... Agent: Harness, Dickey & Pierce, P.L.C

  
12/09/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100311639 - Inhibitors of ncca-atp channels for therapy: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits... Agent: Fulbright & Jaworski, LLP

20100311638 - Method for altering the shape of polymer particles: A process for altering the shape of a polymer particle is disclosed. The process comprises suspending polymer particles in a suspending medium at a temperature that effects melting of the polymer and agitating the suspension for a time sufficient to change the shape of the particles. The shape altered particles... Agent: William J Bundren The Law Office Of William J Bundren

20100311641 - Peptide-based body surface coloring reagents: Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, and oral cavity surfaces. Peptide-based body surface coloring reagents, preferably tooth coloring reagents, are formed by coupling a tooth binding peptide to a pigment binding peptide, either directly or through a... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100311640 - Self-assembling peptide incorporating modifications and methods of use thereof: The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain... Agent: Choate, Hall & Stewart LLP

20100311642 - Use of v2 receptor antagonists in combination with vaso pressinergic agnosts: The combination of vasopressin V2 receptor antagonists and vasopressin receptor agonists (selective or non-selective) is described, including pharmaceutical compositions, including kits, for administering, and methods and uses of such a combination, e.g. for treatment of critical care diseases and conditions requiring control of arterial blood pressure or for treatment of... Agent: Merchant & Gould PC

20100311643 - Use of glp-1 as a therapeutic agent: The present invention is directed to the use of the peptide compound His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100311644 - Isozyme-specific antagonists of protein kinase c: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to... Agent: King & Spalding LLP

20100311645 - Proteins from the webs of nephilengys cruentata, avicularia juruensis and parawixia bistriata spiders isolated from brazilian biodiversity: The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to... Agent: Arent Fox LLP

20100311646 - Method of inhibiting clostridium difficile by administration of oritavancin: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.... Agent: Roylance Abrams Berdo & Goodman, LLP

20100311648 - Melanocortin receptor-specific peptides: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases,... Agent: Morgan Lewis & Bockius LLP

20100311649 - Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R , such as obesity, and diabetes.... Agent: Merck

20100311647 - Use of melanocortins to treat insulin sensitivity: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.... Agent: Alan F. Feeny, Esq.

20100311650 - Treatment for obesity: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.... Agent: Ostrolenk Faber Gerb & Soffen

20100311651 - Use of glp-1 compound for treatment of critically ill patients: Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100311652 - Genetic marker for use in the treatment of leukemia: The invention relates to the use of a genetic marker in a process for analysis of leukemia patients, especially for use in the prediction of the suitability of chemotherapy in a group of leukemia patients. Further, the invention relates to chemotherapeutical agents for use in the therapy of leukemia patients... Agent: Greer, Burns & Crain

20100311653 - Splice variants of gdnf and uses thereof: The present invention relates to Glial Cell Line-Derived Neurotrophic Factor (GDNF) protein and gene and is, in particular, directed to a novel splice variant of GDNF protein, which is encoded by a novel splice variant pre-(γ)pro-GDNF, and secreted under biological regulation.... Agent: Birch Stewart Kolasch & Birch

20100311654 - Modified polysaccharide-based delivery of nucleic acids: The present disclosure provides compositions for enhanced delivery of therapeutic agents. Drug delivery vehicle compositions may include a modified polysaccharide (e.g. chitosan) having at least one secondary amine or at least one tertiary amine and a therapeutic agent such as a therapeutic nucleic acid and/or a therapeutic anionic agent. Various... Agent: Baker Botts L.L.P.

20100311655 - Intranasal carbetocin formulations and methods for the treatment of autism: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors,... Agent: Eckman Basu LLP

20100311656 - Treatment or prevention of respiratory viral infections with alpha thymosin peptides: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.... Agent: Cooley LLP Attn: Patent Group

20100311657 - Hemoglobin compositions: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin,... Agent: Morgan, Lewis & Bockius LLP (sf)

20100311658 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C. (tc)

20100311659 - Novel viii factors for the treatment of type a hemophilia: The present invention relates to improved human FVIII variants having at least one substitution in the A2 and/or C2 domain. The present invention also relates to their uses in the treatment of hemophilia A, particularly in patients with inhibitors.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100311660 - Natriuretic peptide receptor-c agonists: This document relates to methods and materials involved in preferentially activating natriuretic peptide receptor-C polypeptides. For example, agonists of natriuretic peptide receptor-C polypeptides as well as methods for activating natriuretic peptide receptor-C polypeptides are provided herein.... Agent: Fish & Richardson P.C. (tc)

20100311662 - Treatment of acute coronary syndrome with an exendin: The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100311661 - Use of compounds derived from cycloheximide for the treatment or prevention of, in particular, ischaemias and cardiopathies: The present invention relates to the use of certain derivatives of cycloheximide or the pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment or prevention of ischaemias, of cardiopathies, of endothelial disorders, of traumata, of necroses, of pulmonary disorders, of vascular disorders, of forms of shock,... Agent: Connolly Bove Lodge & Hutz LLP

20100311663 - Memory influencing protein: The present invention provides methods and compositions for enhancing and/or impairing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) and/or a PKMζ, inhibitor.... Agent: Scully Scott Murphy & Presser, PC

20100311665 - Method and composition for potentiating an opiate analgesic: Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans.... Agent: Marshall, Gerstein & Borun LLP

20100311664 - Methods for reducing oxidative damage: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three... Agent: Foley & Lardner LLP

20100311666 - Cosmetic use of a protein belonging to the ribonuclease family: The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of... Agent: Oliff & Berridge, PLC

20100311667 - Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same: A compound of the formula I: R-A-Gly-His-B (I) wherein: A and B are independently of each other a L-lysine residue, a D-lysine residue, or a L- or D-lysine residue in which the NH2 group of the side chain comprises a modification, where-in said modification is (i) a replacement with a... Agent: Schwegman, Lundberg & Woessner, P.A.

20100311668 - Personal care and cosmetic composition containing tetrapeptides with the motifs gx1x2g, px1x2p, or px1x2k: The present invention relates to topical personal care and skin care compositions comprising: a) a safe and effective amount of a tetrapeptide selected from the group of tetrapeptides with the motif GX1X2G, PX1X2P, or PX1X2K, derivatives thereof, and mixtures thereof; b) a safe and effective amount of at least one... Agent: Scully Scott Murphy & Presser, PC

20100311669 - Compounds that bind to p185 and methods of using the same: Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual... Agent: Woodcock Washburn LLP

20100311670 - Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation: Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to... Agent: Fish & Richardson P.C. (tc)

20100311671 - Transdermal delivery of pkc modulatory peptides through microporated skin: Disclosed herein are methods for transdermal delivery of PKC modulatory peptides. Generally, methods comprise the delivery of an isozyme specific PKC peptide modulator through skin that has been microporated, e.g., with an array of microneedles. Such methods may be used to administer therapeutically effective amounts of an isozyme selective PKC... Agent: King & Spalding LLP

20100311672 - Vesiculins: The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and... Agent: Greenlee Sullivan P.C.

20100311673 - Sulfanyl-tetrahydropyran-based compounds and methods of their use: Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20100311674 - Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression: Oral pharmaceutical compositions or functional foods with a mechanism of multi-target receptor retroaction for treating depression comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression Paroxetine in the art, the present invention has significant anti-depression efficacy.... Agent: Volpe And Koenig, P.C.

20100311676 - Compositions containing sesamin-class compound(s) and quercetin glycoside(s): The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced.... Agent: Drinker Biddle & Reath (dc)

20100311675 - Novel method for preparing purified extracts of harpagophytum procumbens: The present invention relates to a method for preparing a concentrated extract of Harpagophytum procumbens, in liquid or dry form, having a harpagoside titre greater than or equal to 5%, which method comprises a step of purifying a crude extract of Harpagophtyum procumbens in liquid form in aqueous phase by... Agent: Stites & Harbison PLLC

20100311677 - Active ingredient combinations having insecticidal and acaricidal properties: The novel active compound combinations comprising compounds of the formulae (I) and (II) have very good insecticidal and acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100311679 - Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and... Agent: Connolly Bove Lodge & Hutz LLP

20100311678 - Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways: This invention features methods and compositions for treating cancer and modulating signal transduction and metabolism pathways. For example, the methods and compositions of the invention can be used to kill or inhibit the growth or spread of cancer cells. The invention also features a method of identifying a compound that... Agent: Clark & Elbing LLP

20100311680 - Synthesis of novel neamine derivatives and use thereof as antibacterial agents: i

20100311807 - Methods for identifying diabetes and obesity therapeutics: The invention relates to inhibition of Par-1b kinase activity for treating disorders including diabetes and obesity. The invention also relates to screening for compounds or compositions that inhibit the kinase activity of Par-1b protein, which compounds and compositions are useful in the treatment of diabetes and obesity, as well as... Agent: Wolf Greenfield & Sacks, P.C.

20100311808 - Methods, compositions and drug delivery systems for intraocular delivery of sirna molecules: Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.... Agent: Allergan, Inc.

20100311810 - Modulation of diacylglycerol acyltransferase 2 expression: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression... Agent: Mcdermott Will & Emery LLP

20100311812 - Rna interference mediated inhibition of intercellular adhesion molecule (icam) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression... Agent: Merck C/o Sirna Therapeutics, Inc.

20100311811 - Rna-mediated epigenetic regulation of gene transcription: The invention provides a method of regulating transcription of a gene that is a target for an epigenetic regulator; a method of characterizing the transcriptional activity of such a gene; a method of screening for a chromosomal element (CE) for an epigenetic regulator of a target gene; an isolated complex... Agent: Weaver Austin Villeneuve & Sampson LLP

20100311809 - Viral vector system, a composition comprising the viral vector system and its use: The present invention relates to a viral vector system comprising at least one viral vector and at least one regulable expression cassette inserted in said viral vector applicable for the treatment of virally infected cells. Preferably, the at least one regulable expression cassette comprises at least one transactivator, at least... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100311822 - Ace2 activation for treatment of heart, lung and kidney disease and hypertension: ACE2 activating compounds for prevention and treatment of cardiovascular disease, kidney disease, lung disease and hypertension are disclosed. Also disclosed are methods of diagnosing cardiovascular disease, kidney disease, lung disease and hypertension by measuring ACE2 expression or nucleotide polymorphism analysis.... Agent: Fulbright & Jaworski L.L.P.

20100311823 - Agent for regulating bone formation: The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled... Agent: Foley And Lardner LLP Suite 500

20100311813 - Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders relating to androgen metabolism, their pharmaceutical compositions, their uses and treatment method: These anti-androgenic active principles are specific to reach their molecular target, which is circumscribed to the site of application. The oligonucleotides described inhibit the androgen receptor (AR) expression at very low concentrations in skin and hair follicle primary cell cultures, through a mechanism implying the reaching of, and the hibridizing... Agent: NeifeldIPLaw, PC

20100311818 - Diterpene modulator of macrophage phagosomal maturation: Novel uses for diterpene modulators of macrophage phagosomal maturation are provided. The diterpene isotuberculosinol is used as an immune modulator, assay for pharmaceutical compositions and an isolated Mycobacterium tuberculosis labdane-related diterpenoid virulence factor. A method of treating Mycobacterium tuberculosis infectivity is further provided.... Agent: Mckee, Voorhees & Sease, P.L.C

20100311816 - Mcp-1 binding nucleic acids and use thereof: Nucleic acid molecules that bind MCP-1 can be used for treating or preventing chronic diseases, such as, respiratory disease, kidney disease or system lupus erythematosus.... Agent: Mdip LLC

20100311819 - Method for down-regulating gene expression in fungi: The present invention concerns methods for controlling fungus infestation via dsRNA mediated gene silencing, whereby the intact fungus cell(s) are contacted with a double-stranded RNA from outside the fungal cell(s) and whereby the double-stranded RNA is taken up by the intact fungal cell(s). In one particular embodiment, the methods of... Agent: Wolf Greenfield & Sacks, P.C.

20100311815 - Mir-101 cancer markers: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers.... Agent: Casimir Jones, S.c.

20100311824 - Modulation of forkhead box o1a expression: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with... Agent: Mcdermott Will & Emery LLP

20100311814 - Modulation of stat5 expression: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20100311820 - Nucleic acid modulators of glycoprotein vi: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that... Agent: King & Spalding

20100311817 - Rationally-designed single-chain meganucleases with non-palindromic recognition sequences: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant... Agent: Wilmerhale/boston

20100311821 - Synthetic vector: The present invention includes compositions including a polymer-peptide hybrid and one or more isolated polynucleotides, wherein the polymer of the polymer-peptide hybrid includes a neutral amphiphilic block copolymer, wherein the peptide of the polymer-peptide hybrid is covalently attached to the hydrophobic block of the amphiphilic block copolymer, and wherein the... Agent: Mueting, Raasch & Gebhardt, P.A.

20100311681 - Stable 6-methoxy-2',3'-dideoxyguanosine, method for preparing the same and pharmaceutical composition containing the same: A stable 6-methoxy-2′,3′-dideoxyguanosine comprises 6-30% water content. It is prepared by absorbing water in 6-methoxy-2′,3′-dideoxyguanosine with less than 6% water content at low temperature and certain humidity, or drying 6-methoxy-2′,3′-dideoxyguanosine with more than 30% water content. The stable 6-methoxy-2′,3′-dideoxyguanosine can be used to prepare medicament composition, and be used to... Agent: Gottlieb Rackman & Reisman PC

20100311682 - Antimelancholic medicine prepared with jujube camp materials: The antimelancholic medicine or health products prepared with jujuba cAMP materials and the preparative method are provided in the present invention.... Agent: Volpe And Koenig, P.C.

20100311683 - Cytidine analogs for treatment of myelodysplastic syndromes: The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome a therapeutically effective amount of a cytidine analog. The cytidine analog includes 5-aza-2′-deoxy cytidine, 5-azacytidine, 5-aza-2′-deoxy- 2′,2′-difluorocytidine, 5-aza-2-40 -deoxy-2′-fluorocytidine, 2′-deoxy-2′,2′-difluorocytidine, cytosine 1-β-D-arabinofuranoside, 2(1H)... Agent: Jones Day

20100311684 - Novel tricyclic nucleosides or nucleotides as therapeutic agents: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.... Agent: Seed Intellectual Property Law Group PLLC

20100311685 - Pharmaceutical composition containing an n-phenylpyrazole derivative and glycofurol, use for the preparation of a topical veterinary medicament for combating fleas: The present invention relates to a liquid pharmaceutical composition containing an N-phenylpyrazole derivative as active ingredient and alpha-(tetrahydrofuranyl)-omega-hydroxypoly(oxy-1,2-ethanediyl) as solvent, and also to the use of such a composition for the preparation of an antiparasitic veterinary medicament for topical application, for the prevention and/or treatment of infestations with fleas in... Agent: Alston & Bird LLP

20100311686 - Nutraceutical composition and methods for preventing or treating multiple sclerosis: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.... Agent: Licata & Tyrrell P.C.

20100311687 - Polysaccharides derivatised with citric acid: Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100311688 - Ophthalmic formulations, methods of manufacture, and methods of using same: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. Methods of manufacture are also provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100311690 - Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism: The present invention relates to novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. The invention also relates to compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism.... Agent: Merchant & Gould PC

20100311689 - Combination therapy with organic arsenicals: The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of... Agent: Ropes & Gray LLP

20100311691 - Compositions of s-alkylisothiouronium derivatives for treating upper respiratory congestion: The present invention provides intranasal pharmaceutical compositions comprising an S-alkylisothiouronium derivative and methods of treating or alleviating upper respiratory and oral-pharyngeal congestions by pharmaceutical compositions comprising the S-alkylisothiouronium derivative.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100311692 - Pharmaceutical formulation containing choline alfoscerate: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.... Agent: Dowell & Dowell P.C.

20100311694 - set of geldanamycin derivatives and their preparation methods: A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90 (Hsp 90) inhibiting agents which have the utility as antivirus... Agent: Harness, Dickey & Pierce, P.L.C

20100311693 - Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives: s

20100311695 - Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or... Agent: Foley And Lardner LLP Suite 500

20100311696 - Topical skin treatment composition: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin. The present invention further relates to the topical application to the skin of such compositions, and/or preparations containing them, for the prevention... Agent: Sullivan & Worcester LLP

20100311697 - Methods and compositions for the treatment of cns-related conditions: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.... Agent: Wilson Sonsini Goodrich & Rosati Adamas Pharmaceuticals, Inc.

20100311698 - Aqueous based pharmaceutical formulations of water-soluable prodrugs of propofol: The present invention is directed to aqueous based formulations of water-soluble prodrugs of propofol. The formulations comprise in aqueous medium an effective amount of the water-soluble prodrug of propofol in the absence of an antioxidant. The formulations are particularly useful as intravenous injections. The formulations preferably are buffered to a... Agent: Banner & Witcoff, Ltd.

20100311699 - Novel carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20100311700 - Transdermal preparation for external use containing nonsterioidal antiinflammatory/analgesic agent: A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological... Agent: Edwards Angell Palmer & Dodge LLP

20100311701 - Pharmaceutical co-crystal compositions: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100311702 - 19-nor-steroid derivatives with a 15alpha, 16alpha-methylene group and a saturated 17, 17-spiro-lactone ring, use thereof, and medicaments containing said derivatives: The 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSO2R, where R is hydrogen, C1-C10-alkyl, aryl or C7-C20-aralkyl, R4 is hydrogen or halogen,... Agent: Millen, White, Zelano & Branigan, P.C.

20100311703 - New compounds as adenosine a1 receptor antagonists: This compounds correspond to the formula (I), where: R1 represents and aryl or heteroaryl group optionally substituted by one or more substituents selected from the group consisting of halogen atoms, straight or branched optionally substituted lower alkyl, cycloalkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, or —CO2R′, wherein... Agent: Leason Ellis LLP

20100311705 - Ophthalmologic irrigation solutions and method: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing... Agent: Marcia S. Kelbon, Esq. Omeros Corporation

20100311704 - Pharmaceutical delivery systems for treatment of substance abuse and other addictions: Disclosed are injectable pharmaceutical compositions that contain a therapeutically effective amount of an anti-addictive agent, an anti-inflammatory agent, and a pharmaceutically acceptable liquid carrier, methods of making the compositions, and uses thereof for treating addictions including substance abuse (or addiction to an abused substance) and addictive or compulsive behavior, by... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100311706 - Method of treatment of allergic rhinitis: s

20100311707 - Controlled release delivery system for nasal applications and methods of treatment: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma... Agent: Frommer Lawrence & Haug

20100311708 - Use of nor-bile acids in the treatment of arteriosclerosis: The present invention relates to the use of nor-bile acids and their pharmaceutically acceptable salts, esters and/or derivatives in the treatment arteriosclerosis.... Agent: K&l Gates LLP

20100311709 - 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [f]indazole-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands: The present invention is directed to 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives of formula I (I) as glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20100311710 - Cyclobutanemethanamine inhibitors of monoamine reuptake: The present invention relates to new cyclobutanemethanamine inhibitors of monoamine reuptake, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100311711 - Inhibitors of naaa and methods thereof: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated... Agent: Fish & Associates, PC Robert D. Fish

20100311712 - Modulators of cxcr7: or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with... Agent: Townsend And Townsend And Crew, LLP

20100311714 - 1h-imidazo[4,5-c]quinolinone compounds: The invention relates to the use of 1H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a... Agent: Novartis Institutes For Biomedical Research, Inc.

20100311715 - Alpha carbolines and uses thereof: e

20100311713 - Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, ibs and functional dyspepsia: The present invention relates to new azetidine compounds, to pharmaceutical compositions containing them and the use of said compounds in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. The compounds are neurokinin (NK) antagonists. The present invention further relates to processes for the preparation of the compounds.... Agent: Fish & Richardson P.C. (tc)

20100311716 - Use of inhibitors of jun n-terminal kinases to treat glaucoma: Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.... Agent: Peter Rogalskyj Esq. Braman & Rogalsky LLP

20100311717 - Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs: Methods and compositions for preventing or reducing weight gain and associated metabolic syndrome in patients receiving atypical antipsychotic drugs for treatment of mental illnesses are described. The invention comprises administering to a patient in need of treatment an effective amount of a dopamine agonist in conjunction with an effective amount... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20100311719 - Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.... Agent: Fish & Richardson P.C. (bo)

20100311718 - Treatment of psychoses with dibenzothiazepine antipsychotic: The present invention provides methods for treating depression symptoms associated with bipolar disorder.... Agent: Connolly Bove Lodge & Hutz, LLP

20100311720 - Spiroindoline modulators of muscarinic receptors: The present invention relates to spiroindoline modulators of muscarinic receptors. The present invention also provides compositions comprising such spiroindoline modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100311721 - Compounds: e

20100311722 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100311723 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100311724 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100311725 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100311726 - Reduction of beta-amyloid levels by treatment with the small molecule differentiation-inducing factor: The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted Aβ. The metabolic processing of other γ-secretase substrates normally... Agent: Wolf Greenfield & Sacks, P.C.

20100311728 - Manipulation of brain cdp-diacylglycerol and uses thereof: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided... Agent: Benjamin Aaron Adler Adler & Associates

20100311727 - Therapeutic amine-arylsulfonamide conjugate compounds: o

20100311730 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to... Agent: Swanson & Bratschun, L.L.C.

20100311729 - Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors: processes for the preparation thereof, more generally these compounds for use in the treatment of the human or animal body, in the treatment of an inflammatory or obstructive airway disease, disorders commonly occurring in connection with transplantation, or a proliferative disease, which disease responds to an inhibition of kinases of... Agent: Novartis Institutes For Biomedical Research, Inc.

20100311731 - Fluoroquinolone carboxylic acid molecular crystals: A molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; (b) a DSC melting peak at 288° C.; (c) a 13C NMR spectrum having peaks at... Agent: Bausch & Lomb Incorporated

20100311732 - Novel heterocyclic compounds: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric... Agent: Ladas & Parry LLP

20100311733 - Thiadiazinone derivatives: Compounds of the formula (I), in which R1, Q and Het have the meanings indicated in Claim 1), are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100311734 - Spiro compounds useful as antagonists of the h1 receptor: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100311735 - Inhibitors of human immunodeficiency virus replication: e

20100311736 - Pyridosulfonamide derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100311737 - Pyrimido [4,5-b] -oxazines for use as dgat inhibitors: Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.... Agent: Morgan Lewis & Bockius LLP

20100311738 - Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists: The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists, comprising a) an ultrashort-effective β-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to... Agent: Fulbright & Jaworski L.L.P.

20100311739 - Naphthalene diimide compounds: The invention relates to novel compounds which are naphthalene diimides of general formula (I). The compounds are used in therapy, particularly in cancer treatment.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100311740 - Imidazopyridine derivatives as acid pump antagonists: This invention relates to newly identified imidazopyridine compounds of formula (I), to the use of such compounds in treating GERD and the like.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100311741 - Bicyclosulfonyl acid (bcsa) compounds and their use as therapeutic agents: This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock;... Agent: Swanson & Bratschun, L.L.C.

20100311743 - Azaindoles useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100311744 - Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100311742 - Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kine-toplastid or apicomplexan protozoan with tyrosine kinase inhibitors.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100311745 - 1,3-dihydroisoindole derivatives: Novel 1,3-dihydroisoindole derivatives of the formula (I), in which R1-R3 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20100311747 - Dicycloazaalkane derivates, preparation processes and medical uses thereof: Disclosed are new dicycloazaalkane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and the uses for treatment especially for dipeptidyl peptidase inhibitor (DPP-IV), in which each substitute group of general formula (I) is as defined in specification.... Agent: Brinks Hofer Gilson & Lione

20100311746 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100311749 - 4-benzoyl-1-substituted-piperazin-2-one derivatives as p2x7 modulators: e

20100311748 - Heterocyclic amides useful for the treatment of cancer and psoriasis: The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and... Agent: Astrazeneca R&d Boston

20100311750 - Organic compounds: The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to... Agent: Novartis Institutes For Biomedical Research, Inc.

20100311751 - Solid dispersions containing an apoptosis-promoting agent: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the... Agent: Paul D. Yasger Abbott Laboratories

20100311752 - Substituted pyridazine derivatives: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.... Agent: Ross J. Oehler Cephalon, Inc.

20100311753 - C5ar antagonists: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.... Agent: Townsend And Townsend And Crew, LLP

20100311754 - 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase: Naphthalene-based compounds having linked heterocyclic and aromatic rings capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and methods for treating conditions associated with P38 activity or cytokine activity; more particularly naphthalene-based compounds of... Agent: Sunstein Kann Murphy & Timbers LLP

20100311755 - 1,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method... Agent: Lisa V. Mueller Polsinelli Shughart PC

20100311756 - Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof: The present invention relates to methods for reducing the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular dysfunction following a cardiac insult in a subject in need of treatment thereof. Moreover, the present invention also relates to methods of delaying the onset of heart failure... Agent: Polsinelli Shughart PC

20100311757 - Salarins and tulearins, compositions and uses thereof: Salarines and Tulearins isolated from Fascaplysinopsis sp. sponge and synthetic derivatives thereof are provided.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100311759 - Antiparasitic agent for fish and method of controlling proliferation of fish parasites: l

20100311760 - Heterocyclic antiviral compounds:

20100311758 - Method for diagnosis of inflammatory diseases using calgranulin c: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a... Agent: Millen, White, Zelano & Branigan, P.C.

20100311761 - Perhydroquinoxaline derivatives: The present invention relates to perhydroquinoxaline derivatives, processes for their preparation, their use for the preparation of a medicament and medicaments containing perhydroquinoxaline derivatives.... Agent: The Nath Law Group

20100311762 - Reduction of toxicity of multi-targeting antifolates: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting antifolate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action... Agent: Harness, Dickey & Pierce, P.L.C

20100311763 - Pyridazine derivatives and their use as therapeutic agents: e

20100311764 - Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds: Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders:... Agent: Lexicon Pharmaceuticals, Inc.

20100311765 - Metabolic degradation inhibitors for anti-hyperproliferative agents: The present invention provides methods of increasing an amount of a treatment agent in the body, a cancer or tumor. The methods include administering an inhibitor of the metabolic degradation or conversion of the treatment agent to a subject undergoing treatment for a hyperproliferative disorder with said treatment agent. Methods... Agent: Myers Bigel Sibley & Sajovec

20100311766 - Antibacterial compositions: Compounds of formula (I) have antibacterial activity wherein: m is O or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C3 alkylene, C2-C3 alkenylene or C2-C3 alkynylene radical; X is —C(═O)NH— or —C(═O)O—; R2 and R3 are as defined in the specification.... Agent: Banner & Witcoff, Ltd.

20100311768 - Use of purine derivatives for the manufacture of a medicament: The invention relates to the use of purine derivatives in the manufacture of a medicament for treating pathological conditions in which an imbalance between cell division and apoptosis is involved, and more particularly in which excessive apoptosis is responsible for the pathological condition. According to the invention, a purine derivative... Agent: Oliff & Berridge, PLC

20100311767 - Method for the treatment of amyloidoses: The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an agonist of the P/Q type voltage-gated presynaptic calcium channel to said subject.... Agent: Paul D. Yasger Abbott Laboratories

20100311769 - Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same: The present invention relates to a novel quinazoline-2,4-dione derivative of formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for preventing or treating neurological brain disease.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100311770 - Compound combinations for inhibiting cell division and methods for their identification and use: The present invention provides in vitro assays, e.g., FtsZ GTPase assays, and/or in vivo assays and methods of use thereof to identify particular compounds and combinations of compounds that affect microbial cell division. The invention further provides such compounds and compound combinations, including combinations that result in inhibition of cell... Agent: Choate, Hall & Stewart LLP

20100311772 - Method and compounds for inhibition of cell death: The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2.... Agent: Nutter Mcclennen & Fish LLP

20100311771 - Method of treating movement disorders using barbituric acid derivatives: e

20100311774 - Combination comprising paclitaxel for treating ovarian cancer: The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.... Agent: Hoxie & Associates LLC

20100311773 - Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof: Disclosed are novel anabaseine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100311775 - Novel seh inhibitors and their use: wherein R1, R2, R3, R5, R6, R13, A, B, Y, Z, x, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100311776 - Novel seh inhibitors and their use: wherein R1, R2, R3, R5a, R6a, A, B, K, L, M, Y, Z, l, and m are defined herein, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100311778 - Chromane derivatives as trpv3 modulators: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating... Agent: Kaplan Gilman & Pergament LLP

20100311777 - Spiroheterocyclic pyrrolidine dione derivatives useful as pesticides: A compound of the formula (I) wherein the substituents are as defined in the claims, is useful as a pesticide.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100311779 - Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal compositon containing them: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20100311780 - Nitric oxide amino acid ester compound, composition for increasing nitirc oxide levels and method of use: There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at... Agent: Klauber & Jackson

20100311782 - Substituted piperidinylpropanoic acid compounds and methods of their use: Novel 3,4-disubstituted-4-(3-carbamoylphenyl)-piperidinylpropanoic acid compounds and their salts, including pharmaceutically acceptable salts, pharmaceutical compositions and methods of their use are disclosed. The novel compounds are useful, inter alia, as antagonists of opioid receptors.... Agent: Feldman Gale, P.A.

20100311781 - Synthesis of r-n-methylnaltrexone: This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.... Agent: Progenics Pharmaceuticals, Inc. C/o Wolf, Greenfield & Sacks, P.C.

20100311783 - Stereoselective process and crystalline forms of a camptothecin: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.... Agent: Lucas & Mercanti, LLP

20100311784 - Stereoselective process and crystalline forms of a camptothecin: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.... Agent: Lucas & Mercanti, LLP

20100311785 - Combination therapy for modulating the human sexual response: The invention is directed to compositions and methods for modulating the human sexual response. The compositions comprise two or more pharmaceutically active agents which preferably include an alpha-adrenergic antagonist and a phosphodiesterase inhibitor.... Agent: Howrey LLP - East

20100311786 - Mono- or bicyclic carboxylic acids as off-note blockers: Disclosed are compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by sweeteners such as stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A, and artificial sweeteners such as aspartame, saccharin, acesulfame K (Acesulfame potassium),... Agent: Curatolo Sidoti Co., Lpa

20100311787 - Compounds for inflammation and immune-related uses: s

20100311788 - Salts of clopidogrel with polyanions and their use for manufacturing pharmaceutical formulations: The invention relates to salts of the active ingredient clopidogrel with polyanions. The salts are predominantly in amorphous form, and the polyanions have at least 4 negative charges.... Agent: Fanelli Strain & Haag PLLC

20100311789 - 3-substituted propanamine compounds: e

20100311790 - Amide compounds and plant disease controlling method using same:

20100311791 - N-halogenated amino compounds and derivatives: The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.... Agent: Hamilton Desanctis & Cha, LLP

20100311792 - Benzenesulfonamide compounds and the use thereof: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100311793 - Polymorphs of donepezil salts, preparation methods and uses thereof: Preparation methods of mesylate, para-toluenesulfonate, succinate, tartrate, sulphate, nitrate, phosphate, salicylate, fumarate, maleate, gallate, acetylsalicylate, benzenesulphonate, citrate, aspartate, glutaminate, lactate, gluconate, ascorbate, malonate, malate, sorbate, acetate or formate of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine (i.e., Donepezil). Novel polymorphs formed from these salts and their preparation methods. Co-crystals formed from Donepezil hydrochloride and maleic acid,... Agent: Seed Intellectual Property Law Group PLLC

20100311794 - Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Gilead Sciences Inc

20100311795 - 1,3-dioxane carboxylic acids: The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.... Agent: Ladas & Parry LLP

20100311796 - method for the separation and purification of epothilones: The invention discloses a method for the separation and purification of epothilones, especially discloses a method for the separation and purification of epothilones B and A using normal phase silica gel chromatography, which comprises loading the sample after dissolving the sample containing epothilones B and A with C1-C7 alkyl halide... Agent: Myers Bigel Sibley & Sajovec

20100311797 - Novel compounds: The present invention relates to substituted indoles of formula (I), useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20100311798 - 2-aminooxazolines as taar1 ligands: R1, R2, R2′, X, Y, andn are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100311799 - Polycyclic antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100311800 - Angiotensin ii receptor antagonists: The present invention relates to nitrooxyderivatives of angiotensin II receptor antagonists.... Agent: Arent Fox LLP

20100311801 - Use of tetramic acid derivatives for controlling nematodes: The present application relates to the use of tetramic acid derivatives for controlling soil-dwelling nematodes.... Agent: Bayer Cropscience Lp

20100311802 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl... Agent: Novartis Corporate Intellectual Property

20100311805 - Combination of histone deacetylase inhibitors and radiation: e

20100311803 - Method for reducing inflammatory responses and inflammation: The present invention relates a method of preventing and/or reducing an inflammatory response and/or inflammation in one or more tissues. The method includes delivering to the one or more tissues an effective amount of a substance P receptor antagonist.... Agent: Klarquist Sparkman, LLP

20100311804 - Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.... Agent: Cooley LLP Attn: Patent Group

20100311806 - Novel polymorphic form of rotigotine and process for production: The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X-ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01±0.2 (°2θ), measured with a Cu—Kαirradiation (1.54060), and a process for production thereof, which is useful for the manufacture of a stable medicament... Agent: Harness, Dickey, & Pierce, P.l.c

20100311825 - Novel taxoid-based compositions: The disclosure relates to novel taxoid-based compositions comprising injectable formulations of these derivatives in the form of an emulsion.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100311826 - Cytotoxic xanthone compounds: The present invention relates to xanthone compounds isolated from the plant Psorospermum molluscum Hochr. (Clusiaceae), a Madagascar plant, which are potent cytotoxic agents.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100311827 - Chlorogenic acid derivatives and their use as anti-fungal agents: The invention provides chlorogenic acid derivatives of Formula (I) that are capable of inhibiting the growth of fungal cells and are useful as anti-fungal agents. The invention further provides the methods of inhibiting the growth of fungal cells and methods of treating a fungal infection in an animal by administering... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100311828 - Extracts of sclerocarya birrea: Provided are extracts obtained from the marula fruit (Sclerocarya Birrea) and uses thereof in a great variety of applications, e.g., use in food supplements for engendering an anti-atherogenic effect in healthy and non-healthy subjects (humans and non-human animals) and as agents for treating or preventing various diseases and disorders.... Agent: The Nath Law Group

20100311829 - Novel therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to modulate apoptosis: The present invention relates to the new therapeutic uses of beta-3 adrenergic receptor agonist derivatives in particular to inhibit apoptosis and treat and/or prevent apoptosis-related diseases and disorders.... Agent: Scully, Scott, Murphy & Presser, P.C.

20100311830 - Menthol replacement: e

20100311832 - Lactylates for the prevention and treatment of infections caused by gram positive bacteria in animals: The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1, Formula 1 R2 -COO—[—CH(CH3)—COO]n—R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate... Agent: Westman Champlin & Kelly, P.A.

20100311831 - Reduction of sterols and other compounds from oils: A process for the removal of sterols, specifically cholesterol, from a triglyceride oil, preferably a marine triglyceride oil, said process comprising contacting an oil with an absorbent, specifically TRIS YL™, clay or a mixture thereof, heating the mixture to 100° C. to 210° C., preferably 150° C. to 170° C.,... Agent: Mckeon Meunier Carlin & Curfman LLC

20100311833 - Physiological coolants based on lactoyl esters of menthyl lactate: A method of imparting a physiological cooling effect to a consumer product is disclosed. The method comprises formulating into the consumer product a composition comprising at least one lactoyl ester of menthyl lactate. Also disclosed is a method of providing physiological cooling by contacting skin or mucous membranes with the... Agent: Lyondellbasell Industries

20100311834 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: K&l Gates LLP

20100311835 - Cis-9, trans-11 isomer of conjugated linoleic acid (cla) for treating inflammatory diseases: A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic... Agent: Fox Rothschild LLP

20100311836 - Oil-in-water emulsified cosmetic composition: c

20100311837 - Method for improving storage stability of glutathione: The invention provides a method of improving the preservation stability of glutathione in a solid composition containing glutathione and arginine. In particular, glutathione and arginine are made to be coexistent with an organic acid such as citric acid, tartaric acid, ascorbic acid, malic acid, malonic acid, succinic acid, fumaric acid,... Agent: Leydig Voit & Mayer, Ltd

20100311838 - Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100311839 - Burst drug release compositions: A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent... Agent: Wyeth LLC Patent Law Group

20100311840 - Oral formulations of bis(thiohydrazide amides): Disclosed herein are oral formulations of bis(thio-hydrazide amides) compounds of the following structural formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R7, R8, Z, and Y are defined herein.... Agent: Foley & Lardner LLP

20100311841 - Synthetic sphingolipid analogs: Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.... Agent: Hunton & Williams LLP Intellectual Property Department

20100311842 - Use of 1-phenyl-3-dimethylamino-propane compounds for treating neuropathic pain: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.... Agent: Crowell & Moring LLP Intellectual Property Group

20100311843 - Compositions and methods for the treatment of glomerulonephritis: e

20100311844 - Spontaneously forming ellipsoidal phospholipid unilamellar vesicles: The instant invention relates generally to compositions and methods useful for the spontaneous formation of liposomes wherein the composition comprises anionic long chain lipids in combination with short chain lipids and a prosaposin-derived protein or polypeptide. The liposomes may be useful for treatment of disease, via administration of the liposome... Agent: Barnes & Thornburg LLP

20100311845 - Glycosidase enzymes: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.... Agent: Verenium Corporation Intellectual Property Department

20100311846 - Methods for controlling water amount in a polymer composition or substrate: A method of controlling the amount of water in a polymer composition or substrate is provided. The method includes the step of adding to the polymer composition or substrate a low molecular weight unsaturated fatty acid which optionally includes a stabilizer composition for preventing oxidation of the low molecular weight... Agent: Myers Bigel Sibley & Sajovec

  
12/02/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100305022 - Low molecular weight heparin composition and uses thereof: Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.... Agent: Lando & Anastasi, LLP

20100305023 - Method of delaying the onset of clinically definite multiple sclerosis: A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the... Agent: Cooper & Dunham, LLP

20100305024 - Methods of inhibiting calcineurin with apoe analogs: The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of... Agent: Cooley LLP Attn: Patent Group

20100305025 - Rnase a peptides, fragments and uses thereof: The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject.... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP

20100305026 - Cd44v6 peptides as inhibitors of bacterial infections: The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection.... Agent: Knobbe Martens Olson & Bear LLP

20100305027 - Cyclic peptides comprising at least one aza-b3-aminoacyl residue and their uses: Cyclic peptides having a random alternation of L-α-aminoacyl residues and aza-β3-aminoacyl residues and their uses.... Agent: Young & Thompson

20100305028 - Cholesterol derivatives of inhibitors of viral fusion: The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit... Agent: Merck

20100305029 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a method of killing or immobilizing an insect comprising administering to the insect a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina. The invention further relates to an insecticide composition comprising such a peptide.... Agent: Ballard Spahr LLP

20100305030 - Nanoparticles of therapeutic agents having low water solubility: The invention relates to a water-dispersible derivative of a therapeutic agent having a low water solubility that comprises at least one molecule of said agent covalently bonded to at least one molecule of a hydrocarbon derivative having a squalenic structure or the like. The invention further relates to corresponding nanoparticles.... Agent: Oliff & Berridge, PLC

20100305031 - Peptide having an extending action for half-life of object peptide in plasma: e

20100305032 - Novel glp-1 derivatives: Novel polypeptide derivatives having protracted profile of action.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100305033 - Hydroxyalkyl starch derivatives and process for their preparation: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group,... Agent: Occhiuti Rohlicek & Tsao, LLP

20100305034 - Growth factor isoform: An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof.... Agent: Choate, Hall & Stewart LLP

20100305035 - Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates... Agent: Oliff & Berridge, PLC

20100305036 - Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders: The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100305037 - Cyclosporin derivatives for treating inflammatory diseases and conditions: e

20100305038 - Diagnostic of immune graft tolerance using tmtc3 gene expression levels: The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant... Agent: Crowell & Moring LLP Intellectual Property Group

20100305039 - Production of collagen in the milk of transgenic mammals: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.... Agent: Townsend And Townsend And Crew, LLP

20100305040 - Production of soluble recombinant protein by pi value control of n-terminal: The present invention relates to a method for improving secretion efficiency of a recombinant foreign protein using a polypeptide fragment containing N-region of a signal sequence (directional signal) or variants thereof with the controlled pI value and/or a secretional enhancer composed of a hydrophilic polypeptide with the controlled pI value.... Agent: Klarquist Sparkman, LLP

20100305041 - Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same: The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100305042 - Pharmaceutical compositions and methods for the treatment of prostate cancer: Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent.... Agent: Finnegan/ferring, B.v.

20100305043 - Ccl18 and ccl3 methods and compositions for detecting and treating cancer: The invention relates to methods of treating cancer by administering one or more chemokines that are downregulated in cancerous cells. More specifically, the invention provides methods for treating or preventing cancers such as malignant melanoma by administering a chemokine such as CCL18 and/or CCL3. The invention further provides methods for... Agent: Wolf Greenfield & Sacks, P.C.

20100305044 - Peptide anti-tumor agent: Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.... Agent: Fish & Richardson P.C.

20100305047 - Cyclosporin derivatives for enhancing the growth of hair: s

20100305045 - Omega-3 oil containing ophthalmic emulsions: Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with an omega-3 fatty acid-containing oil having non-polar aliphatic side chains to form a therapeutic non-irritating eye... Agent: Abbott Medical Optics, Inc.

20100305046 - Stable cyclosporine containing ophthalmic emulsion for treating dry eyes: Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 μm including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also... Agent: Abbott Medical Optics, Inc.

20100305048 - Novel use of cytokine inhibitors: The use of substance that inhibits a pro-inflammatory cytokine, such as TNF or IL-1, for the production of a pharmaceutical composition for improving wound healing is disclosed. Also, a method for improving wound healing wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to... Agent: Buchanan, Ingersoll & Rooney PC

20100305049 - Novel wheat allergens: The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20100305050 - Protein product with modified antigenicity: A bovine casein protein hydrolysate prepared using an enzyme having broad spectrum endopeptidase activity has low residual antigenicity properties in mammals compared to intact casein protein, The composition is useful as an ingredient in foods, beverages, pharmaceutical and cosmetic products. A hydrolysate prepared using Alcalase™ with a degree of hydrolysis... Agent: Hunton & Williams LLP Intellectual Property Department

20100305051 - Natriuretic activities: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.... Agent: Fish & Richardson P.C.

20100305052 - Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof: The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100305053 - Use of hesperidin or of a derivative thereof for the prevention and/or treatment of slackened skin: The present invention relates to the oral use of an effective amount of hesperidin or of a derivative thereof as a skin finning agent.... Agent: Oliff & Berridge, PLC

20100305054 - Concentrated aqueous azalide formulations: The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the... Agent: Mcdermott Will & Emery LLP

20100305055 - Combinations of polyene fungicide with cationic surfactants: A solid composition comprising a cationic surfactant, such as the ethyl ester of the lauramide of the arginine mono-hydrochloride (LAE) and a polyene fungicide such as natamycin is provided. The solid composition is the basis for providing solutions of natamycin of increased concentration. The solid composition may be used for... Agent: Renner Otto Boisselle & Sklar, LLP

20100305056 - Cysteine protease inhibitors for the treatment of parasitic disease: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic... Agent: Merck

20100305058 - Individualized cancer treatments: The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100305057 - Synergistic pharmaceutical combination for the treatment of cancer: A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer.... Agent: Frommer Lawrence & Haug

20100305059 - Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia: n

20100305192 - Compositions and methods for short interfering nucleic acid inhibition of nav1.8: The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method... Agent: Merck Patent Department (k-6-1, 1990)

20100305187 - Methods and compounds for treating diseases caused by reactive oxygen species: Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the complex I-mediated ROS production, a medicament containing such compound and methods for screening for such compounds.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100305186 - Methods for mediating gene suppression: The present invention is concerned with methods for enhancing gene suppression in cells and in particular it is concerned with improved methods for enhancing RNAi-mediated gene silencing by manipulation of factors associated with RNAi. The present invention is also concerned with methods for identifying factors which down-regulate as well as... Agent: Sullivan & Worcester LLP

20100305188 - Nucleic acid capable of regulating the proliferation of cell: Provided are an agent for suppressing or promoting cell proliferation, a diagnostic reagent or therapeutic drug for a disease resulting from a cell proliferation abnormality, an agent for inducing apoptosis, an agent for suppressing or promoting the expression of a target gene for a nucleic acid such as a microRNA,... Agent: Leydig Voit & Mayer, Ltd

20100305190 - Nucleic acid complex and nucleic acid delivery composition: The present invention provides a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid... Agent: Sughrue Mion, PLLC

20100305189 - Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization: A pharmaceutical composition including as active agent, an antisens oligonucleotide having the sequence SEQ ID NO: 1 in a concentration from about 0.40 mg/ml to about 2 mg/ml and the use thereof for preventing, stabilizing and/or inhibiting blood and lymph vascularization.... Agent: Young & Thompson

20100305191 - Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering rna: The present invention concerns methods and reagents useful in modulating adenosine A1 receptor (ADORA1) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against ADORA1... Agent: Merck

20100305193 - Rnai-mediated inhibition of gremlin for treatment of iop-related conditions: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20100305195 - microrna mediator of cardiomyopathy and heart failure: Provided herein is a microRNA, specifically, β-myosin microRNA, compositions comprising β-myosin microRNA and methods of inhibiting or reducing expression of β-myosin microRNA. Also provided are genetically modified cells and animals comprising exogenous β-myosin microRNA. Provided herein are methods of screening for agents that modulate β-myosin microRNA expression. In addition, methods... Agent: Fish & Richardson P.C.

20100305198 - Cationic lipids: This invention relates to cationic lipids. More particularly the invention relates to biodegradable cationic lipids having a plurality of cationic headgroups and one or more lipophilic tail groups. The lipids are of utility in various applications, and in particular in permitting transfection of molecules, and in particular DNA and RNA,... Agent: Foley And Lardner LLP Suite 500

20100305196 - Composition for treating prostate cancer (pca): The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane... Agent: Connolly Bove Lodge & Hutz, LLP

20100305197 - Conditionally active ribozymes and uses thereof: This invention relates, at least in part, to conditionally active ribozymes and uses of such ribozymes. Some aspects of this invention relate to the engineering of conditionally active ribozymes. In some embodiments, the splicing activity of such ribozymes is modulated by at least one regulatory element. Some aspects of this... Agent: Wolf Greenfield & Sacks, P.C.

20100305194 - Modified and stabilized gdf propeptides and uses thereof: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders... Agent: Wyeth LLC/finnegan Henderson, LLP

20100305199 - Therapeutic regimen for treating cancer: The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about... Agent: Leydig Voit & Mayer, Ltd

20100305060 - Nucleoside prodrugs and uses thereof: This application provides compositions or compounds as disclosed herein that are suitable for treating hepatic viral diseases, such as hepatitis C(HCV).... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100305061 - Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics: Disclosed are acid polysaccharides characterised by the concomitant presence of alcohol groups esterified with butyric and formic acids.... Agent: Lucas & Mercanti, LLP

20100305062 - Use of alginate oligomers in combating biofilms: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in... Agent: Knobbe Martens Olson & Bear LLP

20100305063 - Water-soluble iron carbohydrate derivative complexes, the preparation thereof, and medicaments comprising them: Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivatisation of one or more maltodextrins with an aqueous hypochlorite solution at an alkaline pH value, wherein when one maltodextrin is used its dextrose equivalent is from... Agent: Rankin, Hill & Clark LLP

20100305064 - Topical skin care compositions: The present invention relates to an oil-in-water emulsion. The emulsion comprises a starch and a quaternary ammonium salt. The concentration of the quaternary ammonium salt is greater than about 0.5 percent by weight of the composition, the concentration of starch is greater than about 3 percent by weight of the... Agent: Philip S. Johnson Johnson & Johnson

20100305065 - Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms: There is provided the use of compounds of formula wherein R1, R2, R3 and E have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as... Agent: Steptoe & Johnson LLP

20100305066 - Fused thiophene derivatives as kinase inhibitors: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100305067 - Antibacterial condensed thiazoles: Compound of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl;... Agent: Banner & Witcoff, Ltd.

20100305068 - Compounds and methods for modulating protein trafficking: Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for producing a protein and identifying compounds that rescue protein trafficking defects.... Agent: Fish & Richardson P.C.

20100305069 - Oxazolidinone containing dimer compounds, compositions and methods to make and use: wherein n is a non-negative integer; wherein each Z is an oxazolidinone-containing moiety having antibiotic activity in vivo upon cleaving, wherein M is independently OR1 or NR1R2; wherein R1 and R2 are independently selected from the group consisting of H, an optionally-substituted hydrocarbyl residue or a pharmaceutically acceptable cation; wherein... Agent: Knobbe Martens Olson & Bear LLP

20100305070 - Treatment or prophylaxis of proliferative conditions: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in... Agent: King & Spalding LLP

20100305071 - Methods for improving healing of an oral lesion using a glycerophosphate salt: Glycerophosphate salts have been found to hasten the healing and rapid scaling of lesions of the mouth. Methods are provided for improving healing of an oral lesion or preventing diseases or conditions related to an oral lesion using a glycerophosphate salt. In particular, methods are provided for preventing diseases or... Agent: Panitch Schwarze Belisario & Nadel LLP

20100305072 - Substituted tetracycline compounds: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100305073 - Amide compounds as boosters of antivirals: The present invention relates to compounds that have CYP450 inhibiting properties and are therefore useful as boosters of certain drugs, i.e. they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered. The invention further provides the use of said compounds as improvers of... Agent: Philip S. Johnson Johnson & Johnson

20100305075 - Composition and method of treating hearing loss: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing... Agent: Howard & Howard Attorneys PLLC

20100305074 - Niacin-based pharmaceutical compositions: The disclosure relates generally to niacin-based pharmaceutical compositions that include at least one pharmaceutical agent capable of treating a niacin-induced side-effect. Accordingly, one aspect of this disclosure is a pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100305077 - Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease: In one aspect, the present invention relates to amino-salicylic-aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in... Agent: Winstead PC

20100305076 - Methods of treatment for ulcerative colitis: Disclosed herein are new treatments for moderate ulcerative colitis in various subject subgroups. The various subject subgroups include Caucasians, non-smokers, subjects under the age of about 65 years, and subjects previously or currently being treated with steroids.... Agent: Fitzpatrick Cella Harper & Scinto

20100305078 - Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties: The presently disclosed subject matter is directed to metallo-oxidoreductase inhibitors having metal binding moities linked to a targeting moiety through a linking group or a direct bond, methods for screening for metallo-oxidoreductase inhibitors, and methods of treating an oxidoreductase related disorder by administering a metallo-oxidoreductase inhibitor to a subject in... Agent: Alston & Bird LLP

20100305079 - Method of treating human preeclampsia employing resibufagenin: A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does... Agent: Eckert Seamans Cherin & Mellott

20100305080 - Novel crystalline salts of montelukast: The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N′-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compositions comprising the salts and... Agent: Merck

20100305081 - Organo-gel formulations for therapeutic applications: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are... Agent: Connolly Bove Lodge & Hutz LLP

20100305082 - Use of fkbpl gene to identify a cause of infertility: Fertility problems affect (1 in 10) couples in Western society, making it one of the most common serious health issues. Despite this, little is known about the causes of infertility, and thus patient counseling and treatment are suboptimal. With infertility being such a common problem, identification of any cause would... Agent: Greenlee Sullivan P.C.

20100305083 - Substituted porphyrins: To improve bioavailability of the catalytic metalloporphyrin-based SOD mimics Mn(III) 5,10,15,20-tetrakis[N-ethylpyridinium-2-yl]porphyrin (MnTE-2-PyP5+) and Mn(III) 5,10,15,20-tetrakis[N,N′-diethylimidazolium-2-yl]porphyrin (MnTDE-2-ImP5+), three new Mn(III) porphyrins, bearing oxygen atoms within side chains, were synthesized and characterized: Mn(III) 5,10,15,20-tetrakis[N-(2-methoxyethyl)pyridinium-2-yl]porphyrin (MnTMOE-2-PyP5+), Mn(III) 5,10,15,20-tetrakis[N-methyl-N′-(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTM,MOE-2-ImP5+) and Mn(III) 5,10,15,20-tetrakis[N,N′-di(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTDMOE-2-ImP5+). The catalytic rate constants for O2′− dismutation (and the related... Agent: Myers Bigel Sibley & Sajovec

20100305084 - Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use: Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers,... Agent: Genentech, Inc.

20100305087 - Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility: A combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support, wherein said solid support is in a water-insoluble particulate form and comprises a material selected from silicic acid, aluminum hydroxide and titanium hydroxide is disclosed. The API is a compound having both, at least one... Agent: Arent Fox LLP

20100305089 - Fused bicycloheterocycle substituted azabicyclic alkane derivatives: The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20100305090 - Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors: The invention relates to meta-substituted phenyl sulfonyl amides of secondary amino acid amides according to the general formula (I), (II), or (III), the production thereof, and the use thereof as matriptase inhibitors, in particular the use thereof as drugs for inhibiting tumor growth and/or metastasization.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100305091 - Pyrazolo[1,5-a]pyrimidine derivatives: Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.... Agent: Merck

20100305092 - Triazole oxadiazoles derivatives: m

20100305088 - Inhibitors of the chemokine receptor cxcr3: This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100305086 - Pharmaceutical compositions for the treatment of pain: This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype α4β2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by... Agent: Paul D. Yasger Abbott Laboratories

20100305085 - Substituted dihydropyrazolones for treating cardiovascular and hematological diseases: The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100305093 - Inhibitors of mtor and methods of making and using: e

20100305094 - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4,... Agent: Merchant & Gould PC

20100305095 - Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs: The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD... Agent: Morgan, Lewis & Bockius LLP (sf)

20100305096 - Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use: Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are... Agent: Genentech, Inc.

20100305097 - N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones: r

20100305098 - Methods of use: A method of treating a disorder such as rheumatoid arthritis or multiple sclerosis in a subject is carried out by administering to the subject a composition comprising a modulator compound of Th1 differentiation or Th17 expansion.... Agent: Myers Bigel Sibley & Sajovec

20100305099 - Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation: The present invention encompasses compounds of general formula (1) wherein A, B, R1-R3, Rx and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100305100 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.... Agent: Hoffmann & Baron, LLP

20100305101 - Leptin genotype and ß-adrenergic agonists: A method of identifying livestock animal subgroups of the same species, from a group of livestock animals of the same species wherein the subgroup has similar genetic predispositions for response to Zilpaterol Hydrochloride (ZH) treatment with respect to marbling, HCW gain, REA size gain, DDMI, % EBF, and YG's. The... Agent: Riches, Mckenzie & Herbert, LLP

20100305102 - Heterocycle-substituted piperazino-dihydrothienopyrimidines: m

20100305103 - Genes differentially expressed in bipolar disorder and/or schizophrenia: This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction... Agent: Weaver Austin Villeneuve & Sampson LLP

20100305105 - Phenylsulfoxyoxazole compound inhibitors of urea transporters: Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the phenylsulfoxyoxazole, phenylsulfoxyimidazole, phenylsulfoxythiazole class of compounds. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating cardiovascular, renal,... Agent: Seed Intellectual Property Law Group PLLC

20100305104 - Oxadiazole diaryl compounds: o

20100305106 - Inhibitors of fatty acid uptake and methods of use: The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2.... Agent: Fish & Richardson P.C.

20100305107 - Quinoline derivatives and their use as 5-ht6 ligands: e

20100305108 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the... Agent: Birch Stewart Kolasch & Birch

20100305109 - Potassium channel modulators: i

20100305110 - Condensed imidazole derivatives as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferable pharmaceutically acceptable salts, thereof, in which R, R1, R2, R3, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100305111 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100305112 - Pyrimidine inhibitors of kinase activity: e

20100305114 - Heterocyclic aromatic compounds useful as growth hormone secretagogues:

20100305113 - Substituted imidazopyridazines as lipid kinase inhibitors:

20100305115 - Inhibitors of human immunodeficiency virus replication: The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100305116 - Compounds comprising a cyclobutoxy group: The present invention relates to compounds comprising a cyclobutoxy group, processes for preparing them, phar-maceutical compositions comprising said compounds and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100305117 - Substituted pteridines useful for the treatment and prevention of viral infections: The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively inhibit replication of Flaviridae such as the hepatitis C virus, and are useful for the prevention and treatment of such viral... Agent: Gilead Sciences Inc

20100305118 - Pyrimidine inhibitors of kinase activity: e

20100305122 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Jones Day

20100305120 - Compounds for treating muscular dystrophy: Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.... Agent: Jones Day

20100305119 - Method for the treatment of anthrax infections: m

20100305121 - Novel antagonists of the human fatty acid synthase thioesterase: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides... Agent: Dla Piper LLP (us)

20100305124 - Acylated aminopyridine and aminopyridazine insecticides: e

20100305123 - Class of histone deacetylase inhibitors: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl,... Agent: Mccormick, Paulding & Huber LLP

20100305127 - Novel compounds: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Glaxosmithkline Global Patents

20100305126 - Pyrimidine inhibitors of kinase activity: e

20100305128 - Pyrimidinyl-thiophene kinase modulators: The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.... Agent: Eli Lilly & Company

20100305125 - Salt of abt-263 and solid-state forms thereof: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.... Agent: Harness Dickey & Pierce, PLC

20100305129 - Compositions and methods for inhibiting growth and metastasis of melanoma: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or... Agent: Dla Piper LLP (us)

20100305130 - Nasal spray device and method of use thereof: A single-use sprayer for nasal anesthesia is disclosed. The single-use sprayer includes a single dose of anesthetic and a delivery system adapted to dispense the single dose of anesthetic into a nostril. The single-use sprayer prevents patient-to-patient contamination, is easy to use and allows for self-administration, and has a simple,... Agent: Andrews Kurth LLP

20100305131 - Substituted aminopropionic derivatives as neprilysin inhibitors: s

20100305132 - Glutaraldehyde based biocidal compositions and methods of use: Provided are biocidal compositions comprising glutaraldehyde and a compound selected from the group consisting of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane; tris(hydroxymethyl)-nitromethane; and a hexahydrotriazine compound. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.... Agent: The Dow Chemical Company

20100305135 - Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia: The present invention is directed to AHCY inhibitors of formula (I) which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the... Agent: Merck

20100305133 - Prolyl hydroxylase inhibitors: e

20100305134 - Specific inhibitors of pteridine reductase with antiparasitic action: The processes for the preparation of alkyl derivatives of N-[4-(2,4-diaminopteridin-6-ylmethylamino)benzoyl]-N-piperidin-2-carboxylic acid and N-[4-(2,4-diaminopteridin-6-ylmethylamino)benzoyl]-N-piperidin-4-carboxylic acid and of N-[4-(2,4-diaminopteridin-6-ylmethylamino)benzoyl]-N-pyrrolidin-2-carboxylic acid and N-[4-(2,4-diaminopteridin-6-ylmethylamino)benzoyl]-N-pyrrolidin-4-carboxylic acid. Their specific properties of inhibition versus Pteridine reductase of parasitic species. The processes for the preparation of alkyl derivatives of 1[4-(quinoxalin-2-ylamino)benzoyl]piperidin-mono and di-carboxylic acid and alkyl derivatives of 1-[4-(quinoxalin-2-ylamino)benzoyl]pyrrolidin-mono... Agent: Steinfl & Bruno

20100305136 - Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide: The present invention provides quinolone analogs derivatized with a sulfonic acid, sulfonate or sulfonamide group, which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs quinolone analogs derivatized with a sulfonic acid, sulfonate or sulfonamide group, and methods of using the... Agent: Cooley LLP Attn: Patent Group

20100305137 - Piperazine derivatives and methods of use: The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.... Agent: Howrey LLP - East

20100305138 - Pyridyl derivatives and their use as therapeutic agents: e

20100305139 - Method of treating abnormal lipid metabolism: The present invention provides a pharmaceutical agent for the treatment and/or prophylaxis of abnormal blood glucose and lipid metabolism associated with eating, for which a sufficient treatment method or a therapeutic drug has not been found.... Agent: Leydig Voit & Mayer, Ltd

20100305140 - Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein X, A, R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100305141 - Tetrahydroindolone derivatives for treatment of neurological conditions: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.... Agent: Loza & Loza LLP

20100305142 - 3-aminoimidazo 1,2-a pyridine derivatives having an sglt1- and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20100305143 - Pyrrolopyrimidine compounds: Compounds of formula (I) are A2B receptor antagonists: wherein Ri is optionally substituted aryl or an optionally substituted monocyclic heteroaryl group having 5 or 6 ring atoms; R2 and R3 are independently selected from hydrogen, or optionally substituted C1-C6 alkyl, C1-C6 alkoxy-(C1-C6)-alkyl, C3-C8 cycloalkyl, aryl, heteroaryl, aryl-(C1-C6)-alkyl, or heteroaryl-(C1-C6)-alkyl; R4... Agent: Banner & Witcoff, Ltd.

20100305144 - Prevention of recurrence of urethral stricture after a conventional treatment: Prevention of recurrence of urethral stricture after a conventional treatment. Composition applicable to the prevention of recurrence of urethral stricture after a conventional treatment, including a pharmaceutically effective amount of halofuginone. Urethral stricture, a common disease, appears secondary to urethritis, urethral infection, urethral inflammation, urethral instrumentation, urethral catheterization, urethral trauma,... Agent: Greenblum & Bernstein, P.L.C

20100305145 - Substituted aminobutyric derivatives as neprilysin inhibitors: e

20100305146 - Method for the production of 1,3-dioxolane-2-ones and carboxylic acid esters by means of transacylation in basic reaction conditions: The invention relates to a method for producing 1,3-dioxolane-2-ones of general formula (3) in basic reaction conditions by reesterifying the respective ester of general formula (1) in which R1 to R5 have the meanings indicated in the claims and the description. The invention further relates to a method for producing... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100305147 - Chemically modified small molecules: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared... Agent: Jones Day

20100305148 - Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications: The present invention is related to 10,20-di-O ester derivatives of camptothecin and pharmaceutical formulations thereof. The compounds and pharmaceutical formulations of the present invention possess increased biological life span and bioavailability and reduced toxicity, while maintaining anti-cancer activity.... Agent: Leydig Voit & Mayer, Ltd

20100305149 - Polyal drug conjugates comprising variable rate-releasing linkers: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.... Agent: Wilmerhale/boston

20100305151 - O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100305150 - Tuberous sclerosis treatment: Rapamycin derivatives for use in the treatment of neurocutaneous disorders.... Agent: Novartis Corporate Intellectual Property

20100305152 - Method of inhibiting the growth of helicobacter pylori: The shikimate pathway links metabolism of carbohydrates to biosynthesis of aromatic compounds, which is an attractive target for the rational drug and herbicide design because it is essential in algae, higher plants, bacteria, and fungi, but absent from mammals. Thus, the present invention provides a method of inhibiting the growth... Agent: Wpat, PC Intellectual Property Attorneys

20100305153 - Aminoisoquinoline thrombin inhibitor with improved bioavailability: The invention relates to the compound N-(2-oxo-2-propoxyethyl)-β-phenyl-D-phenyl-alanyl-N-[(1-amino-6-iso-quinolinyl)methyl]-L-prolinamide or a pharmaceutically acceptable salt thereof, to a pharmaceutical composition comprising said compound, as well as to the use of the compound for the manufacture of a medicament for treating or for preventing thrombin mediated diseases.... Agent: Organon Usa, Inc. C/o Merck

20100305154 - Prolyl hydroxylase inhibitors: e

20100305156 - Inhibitors of c-met protein kinase: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Inc.

20100305155 - Substituted pyrazole inhibitors of c-met protein kinase: The present invention relates to compounds of formula I, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Inc.

20100305157 - derivatives of dicarboxylic amino acids and their application in the treatment of neurodegenerative diseases: Products of a general formula (I) and their use in the manufacture of medicines useful for the treatment of neurodegenerative diseases such as Alzheimer's disease or, in general, any disease or pathology produced by alterations of biological functions that can be treated or therapeutically modified by these products.... Agent: Merchant & Gould PC

20100305158 - Method for the treatment or prevention of lower urinary tract symptoms: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.... Agent: Brinks Hofer Gilson & Lione

20100305159 - Crystalline form of piperidine compound: The present invention is to provide a crystalline form of (2R,4S)-1-{N-(3,5-bistrifluoromethylbenzyl)-N-methyl}aminocarbonyl-2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethylaminocarbonyloxy)piperidine or a solvate thereof.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100305160 - Anesthetic methods and compositions: The present invention relates to compositions and methods use in pain reduction, including but not limited to, peripheral nerve blocks. In particular, the present invention relates to compositions and methods for the administration of perineural dexmedetomidine and ropivacaine in combination for increased antinociception in peripheral nerve blocks. In addition, this... Agent: Casimir Jones, S.c.

20100305161 - Combinations of fungicidal azoles and pyrion compounds: The present invention relates to combinations of a fungicidal triazole, or a salt thereof, and a pyrion compound, or a salt thereof, which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a fungicidal triazole, or a salt thereof, selected from the... Agent: Philip S. Johnson Johnson & Johnson

20100305162 - Methods for the synthesis of pyridoxamine: e

20100305163 - Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs: Aspects of the invention relate to pharmaceutical formulations comprising an NSAID and acid reducer drug for therapeutic purposes, and methods of preparing the same. Further aspects of the invention relate to fixed dose pharmaceutical formulations comprising naproxen, or pharmaceutically acceptable salts thereof, and esomeprazole, or pharmaceutically acceptable salts thereof.... Agent: Dr. Reddy''s Laboratories, Inc.

20100305164 - 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases: or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and a method for the treatment of an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, involving administering to a patient in need of such treatment a... Agent: Intellectual Property / Technology Law

20100305165 - Thiocolchicine derivatives, method of making and methods of use thereof: Disclosed herein are thiocolchicine derivatives suitable for use as muscle relaxants, methods of making the derivatives, and compositions comprising the derivatives.... Agent: Cantor Colburn LLP

20100305166 - Novel compounds: s

20100305167 - Administration of an inhibitor of hdac: Methods of treating patients with SNDX-275 are provided.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100305168 - Personal-care composition comprising a cationic active: In one embodiment, a personal-care composition in the form of an oil-in-water emulsion comprises an anionic pairing agent, a cationic active, and an anionic thickener. In another embodiment, the anionic pairing agent is pre-formed from the neutralization of an acid with a base. In another embodiment, the anionic pairing agent... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100305169 - Personal-care composition comprising a cationic active: A personal-care composition in the form of an oil-in-water emulsion comprises a water phase, an oil phase, an anionic pairing agent, a cationic active, and an anionic thickener. In one embodiment, the anionic pairing agent is pre-formed from the neutralization of an acid with a base. In another embodiment, the... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100305170 - Agents for combating plant pests: p

20100305171 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent: Cantor Colburn LLP

20100305172 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent: Cantor Colburn LLP

20100305173 - Hydroxyethylamino sulfonamide derivatives: This invention relates to novel hydroxyethylamino sulfonamides, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100305174 - Novel heterocyclic derivatives: The present invention relates to novel heterocyclic derivatives of formula (I) and their pharmaceutically acceptable salts, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts, their pharmaceutical compositions, and their prodrugs thereof. The present invention more particularly provides novel compounds... Agent: Sughrue Mion, PLLC

20100305175 - Pharmaceutical latrunculin formulations: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v,... Agent: Howery LLP

20100305176 - (s,r.)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent: Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated... Agent: Arent Fox LLP

20100305177 - Prophylactic or therapeutic agent for diabetic maculopathy: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined... Agent: Burr & Brown

20100305178 - Pharmaceutical composition: A topical composition comprises at least 5-wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves... Agent: Bacon & Thomas, PLLC

20100305179 - Oral sustained-release tablet: t

20100305180 - Inhibitors of ubiquitin e1: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.... Agent: Cantor Colburn LLP - National Institutes Of Health

20100305181 - Methods for treating a variety of diseases and conditions, and compounds useful therefor: In accordance with the present invention, there are provided novel compounds that have a variety of properties, i.e., antioxidant, anti-inflammatory, antiviral, antibacterial, and antifungal properties. Invention compounds, therefore, have the ability to impart a variety of beneficial physiological effects, e.g., to protect neurons and/or to promote neuroregeneration and/or to promote... Agent: Foley & Lardner LLP

20100305182 - Compounds and methods for modulating communication and virulence in quorum sensing bacteria: The present invention provides compositions and methods for modulating the communication and virulence of quorum sensing bacteria. In various exemplary embodiments, the invention provides a combinatorial library of quorum sensing compounds including synthetic analogs of naturally occurring and non-naturally occurring acyl-homoserine lactone (AHL) analogs, and methods of synthesizing and using... Agent: Greenlee Sullivan P.C.

20100305184 - Inhibitors of the atb(0,+) transporter and uses thereof: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100305183 - Method and composition for reducing reperfusion injury: The present invention relates to a method of preventing and/or reducing reperfusion injury to a tissue, organ, or organ system in a subject. The method includes administering to the subject an effective amount of a substance P receptor antagonist.... Agent: Klarquist Sparkman, LLP

20100305185 - Diagnostic method: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.... Agent: Dechert LLP

20100305200 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Wilson, Sonsini, Goodrich & Rosati

20100305202 - Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same: The present invention relates to a lyophilized pharmaceutical composition for injection having superior storage stability comprising a taxoid, and a method thereof. More specifically, the present invention relates to a lyophilized pharmaceutical composition for injection having improved solubility and stability of dilution compared to the conventional preparations by dissolving a... Agent: Frommer Lawrence & Haug

20100305201 - Method of treating a tumor and biodistribution of a drug delivered by worm-like filomicelles: Provided are filomicelle nanocarrier systems for the controlled transport and bioselective delivery of encapsulatable, cytotoxic active agents contained therein, particularly anticancer agents. Further provided are methods for controlling destabilization of the filomicelle membrane and the resulting hydrolysis-triggered, controlled release of the active agent(s) encapsulated therein by controlling the blend ratio... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100305203 - Method for modulating claudin mediated functions: Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of... Agent: Sughrue Mion, PLLC

20100305204 - Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists: The present invention relates to the use of acetyl L-carnitine, or a pharmaceutically acceptable salt thereof, for the prevention of the adverse effects, such as osteoporosis, weight gain and edema, due to the use of PPAR-gamma agonists selected from the group consisting of spirolaxine or a glitazonederivative selected from the... Agent: Lucas & Mercanti, LLP

20100305205 - Composition and/or method for preventing recurrence of stroke: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the... Agent: Birch Stewart Kolasch & Birch

20100305206 - Modulation of nitric oxide synthases by betaines: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both... Agent: Hovey Williams LLP

20100305207 - Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof: This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition.... Agent: Glaxosmithkline Global Patents

20100305208 - Gastric retention controlled drug delivery system: i

20100305209 - Articles of manufacture releasing an active ingredient: The present invention relates to articles of manufacture having a formulation distributed therein, wherein the formulation comprises an active agent which manifests a desirable property when released from the articles of manufacture. The present invention also relates to methods for manufacturing these articles of manufacture, to vehicles for applying the... Agent: Woodcock Washburn LLP

20100305210 - S-alkylisothiouronium derivatives for treating abnormal uterine bleeding disorders: The present invention relates to methods for treating uterine hypercontractility disorders. In particular, the present invention relates to methods for treating abnormal uterine bleeding and dysmenorrhea comprising administering to women suffering from such disorders a pharmaceutical composition comprising an S-alkylisothiouronium derivative.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100305211 - Gentle-acting skin-disinfectants and hydroalcoholic gel formulations: Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the... Agent: Baker Botts L.L.P.

20100305212 - Therapeutic compounds: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.... Agent: Edwards Angell Palmer & Dodge LLP

20100305213 - Treatment of heart disease using beta-blockers: The present invention relates to a method of reversing the electrophysiological cardiac remodeling of animals with heart disease. More specifically, the method includes administering to an animal in need thereof a β-adrenoceptor blocker.... Agent: Bayer Healthcare LLC

20100305214 - Use of a monoterpene to increase tissue repair: The invention relates to the use of a monoterpene to increase biological tissue repair, i.e. tissue regeneration or healing, the cosmetic use of a monoterpene to increase biological tissue repair of skin or a mucosa in an individual and the use of a monoterpene for the manufacture of a pharmaceutical... Agent: Davidson, Davidson & Kappel, LLC

20100305215 - Dermal regeneration enhancer: An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100305216 - Optically active muscone composition and fragrances or cosmetics containing the same: (Means for resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture... Agent: Fitzpatrick Cella Harper & Scinto

20100305217 - High performance membrane: The invention relates to a micro-porous membrane comprising a porous membrane carrier made of a first polymeric material (A) and comprising a second polymeric material (B) intimately divided throughout the porous membrane carrier, wherein the porous membrane carrier comprises a plurality of interconnected polymeric fibers, fibrils, filaments and/or lamellae having... Agent: Nixon & Vanderhye, PC

20100305218 - Nanoemulsions: The present invention relates to oil-in-water nanoemulsions, processes for their preparation and their use as delivery vehicles for active components for use in opthalmological, dermatological, food, cosmetic, pharmaceutical, agrichemical, textile, polymer and chemical applications. The oil-in-water nanoemulsion comprises up to 40 volume % of an oil phase comprising at least... Agent: Ladas & Parry LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.25726 seconds

PATENT INFO